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Abstract  
 
The H
+
-coupled transporter peptide transporter 1 (PepT1) is found primarily in the intestine and 
is capable of transporting dietary di- and tripeptides as well as peptides produced by bacteria.   
However, little is known about the ontogeny of PepT1 in the piglet.  The first part of this thesis 
describes the investigation of the effects of development and diet on peptide transport in the 
intestine of the Yucatan miniature piglet. Dipeptide transport was significantly higher in the ileal 
section in the youngest age group (1 week) compared to the other suckling groups (p<0.05); 
however,  all suckling piglet groups demonstrated lower ileal transport compared to post-weaned 
pigs. These results suggest that peptide transport in the small intestine is important during the 
first week of suckling and again with diet transition following weaning. The objective of the 
second part of this thesis was to determine the impact of enterally delivered dipeptide-containing 
diets on indices of intestinal adaptation in neonatal piglets after intestinal resection, as PepT1 is 
preferentially maintained over free amino acid transporters in situations of gut stress such as 
short bowel syndrome.   In this model no evidence was found that enteral dipeptides provide 
specific adaptive benefits compared to constituent amino acids.  However, the dipeptide-
containing diets reduced pro-inflammatory cytokine concentrations in the mucosa (p<0.05).  One 
dipeptide in particular, cysteinyl-glycine, supported greater villus height compared to all other 
dipeptides and greater crypt depth compared to alanyl-glutamine yet no dipeptide diet altered 
intestinal morphology compared to the free amino acid control diet.  This study demonstrated 
that while there was no explicit morphological benefit of enteral dipeptides over their constituent 
free amino acids, there was the potential for the amelioration of intestinal inflammation by 
reducing pro-inflammatory cytokines.  As PepT1 is also capable of transporting bacterial 
peptides were then investigated intestinal response to a pro-inflammatory peptide, formyl-
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methionyl-leucyl-phenylalanine (fMLP) alone or in combination with cysteinyl-glycine in a 
model of intestinal atrophy.  Piglets received parenteral nutrition (PN) for 4 d to induce atrophy 
while littermates remained with the sow.  In both dietary treatments, intestinal segments exposed 
to fMLP had higher mucosal pro-inflammatory cytokines with this inflammatory effect being 
attenuated when cysteinyl-glycine was co-perfused with this bacterial peptide (p<0.05). 
Morphologically, fMLP exposure did not alter villus height or crypt depth in sow-fed animals; in 
contrast, intestinal segments from PN-fed piglets exposed to fMLP had reduced villus height 
compared to unexposed loops.  Inclusion of cysteinyl-glycine was effective at attenuating a 
bacterial peptide-induced inflammatory response in the injured SI.  This may be due to efficient 
dipeptide uptake in a situation of impaired free amino acid absorption, and/or competitive 
inhibition of fMLP uptake.   Through the use of in vivo piglet models, these studies have 
contributed to the understanding of peptide transport in health and disease states in addition to 
demonstrating the potential benefits of enteral dipeptide provision.   
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Chapter 1: Literature Review 
1.1 Protein digestion and amino acid transport 
Protein is an essential part of a complete daily diet. A typical Western diet usually contains 
70-100 g protein per day. Of this total protein, about 95-98% is completely digested and absorbed 
(Erickson et al., 1995).   After initiation of digestion in the stomach, dietary products are moved into 
the small intestine where pancreatic enzymes continue to break down complex compounds into 
absorbable products.   Through this gastrointestinal processing, protein is broken down into di/tri-
peptides, comprising roughly 80% of the total protein, with the remaining 20% being reduced to free 
amino acids (Ganapathy V, 2006).  These resulting products of protein digestion are absorbed 
from the lumen of the small intestine via specific transport mechanisms found on enterocytes, 
epithelial cells primarily responsible for nutrient uptake.  The mechanism by which an individual 
amino acid is absorbed by the intestine varies depending on the amino acid.  Free amino acid 
transporters can be classified into five different groups: 1) neutral amino acids, 2) cationic amino 
acids, 3) anionic amino acids,  4) proline, hydroxyproline, lysine and  5) taurine, β-amino acids 
(Broer, 2008).  Certain amino acids may be transported by more than one system, thereby 
providing redundancy (Broer, 2008). The activity of the transporters depends on the 
concentration and variety of amino acids present.   While these systems are capable of 
transporting the free amino acid products of protein digestion, another transporter is required for 
the removal of di/tripeptides from the lumen of the small intestine (Daniel, 2004).. There are 
multiple benefits to the transport of peptides over free amino acids.  Uptake of di/tripeptides by an 
apical peptide transporter, PepT1, requires the same amount of energy that is required to transport a 
single free amino acid (Daniel, 2004). Additionally, it is more efficient to transport amino acids in 
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small peptide form compared to transporting their constituent free amino acids because peptides 
demonstrate faster rates of uptake while requiring the same amount of energy (Gilbert et al., 2008b). 
Investigation of PepT1 has begun to reveal a new facet of amino acid uptake, as well as the 
evolutionarily conserved nature of peptide transport. 
1.2 Introduction to Proton Oligopeptide Transporters 
 Proteins capable of moving small peptides across membranes have been grouped into a 
transporter superfamily known as proton oligopeptide transporter, or POT.  Members of this 
family are found in most organisms with a significant degree of evolutionary conservation 
through bacteria, yeast, plants and animals (Daniel et al., 2006).  All members of this family of 
transport proteins are believed to utilize a proton gradient to drive the uptake of their substrates 
across cell membranes.  Currently there are 40 members of this superfamily, however many of 
those predicted to transport oligopeptides in C. elegans, A. thaliana and E. coli have yet to 
experimentally demonstrate peptide transport (Meredith and Boyd, 2000).  The inclusion of these 
putative peptide transporters is based on the detection of a specific protein sequence, PTR2, 
currently used as an identifier for potential peptide transporters.  There are currently five peptide 
transporters identified in mammals, varying in tissue distribution but with similarities in 
substrate specificity (Daniel and Kottra, 2004).  Classed predominantly as members of the 
SLC15 solute carrier family of transporters, they are SLC15A1, also known as PepT1, 
SLC15A2/PepT2, SLC15A3/ PHT 2 and SLC15A4/ PHT 1 (Daniel and Kottra, 2004).  The fifth 
peptide transporter, HPT1, has greater similarity to cadherins rather than its fellow peptide 
transporters (Dantzig et al., 1994).   
 
1.2.1 Peptide Transporter 1 (SLC15A1) and Peptide Transporter 2 (SLC15A2) 
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 The first identified peptide transporter, PepT1 (SLC15A1), was cloned from a rabbit 
intestinal cDNA library (Fei et al., 1994).  Shortly thereafter the peptide transporter PepT2 was 
first isolated from a human kidney cDNA library (Liu et al., 1995).  Of the members of the POT 
superfamily, PepT1 and PepT2 have received the most investigative attention.  Using 
immunohistochemistry, PepT1 was localized to the apical membrane of enterocytes (Ogihara et 
al., 1996).  PepT2 was not found in the intestine, but rather in the epithelium of the kidney, lung, 
mammary glands as well as regions of the central nervous system (Shen et al., 1999, Rubio-
Aliaga and Daniel, 2002).  PepT1 and PepT2 have many similarities in protein structure and 
sequence.  Both share putative sequences illustrating the potential for 12 trans-membrane 
domains while PepT2 shares 50% identity and 70% similarity to the previously identified PepT1 
(Liu et al., 1995).  Significantly, the sequence similarities are much higher in the trans-membrane 
regions than in the amino- and carboxy-terminus suggesting conservation of functionally 
important residues.  Despite these similarities there are important differences found between the 
substrate specificities of these peptide transporters.  PepT2 showed a higher affinity for 
dipeptides compared to PepT1 in rabbit and human samples (Amasheh et al., 1997, 
Ramamoorthy et al., 1995).  PepT1 is considered a low-affinity/high-capacity peptide transporter 
whereas PepT2 is high-affinity/low-capacity.  The primary function of PepT1 is the absorption of 
dipeptides from the nutritionally rich intestinal lumen, whereas PepT2 removes peptides at 
relatively low concentration from the tubules of the kidney; as such, this particular adaptation is 
physiologically beneficial.  Early in situ studies employed the everted jejunal ring model and 
exposed the tissue to hydrolysis-resistant oligopeptides of two, three or four amino acid residues 
to describe the structure affinity relationships of PepT1.  It was determined that only 
di/tripeptides were transported across the epithelial barrier of the small intestine; tetrapeptides 
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were not transported in this model (Daniel and Kottra, 2004).  Drugs that are structurally similar 
to small peptides are also transported by PepT1 and computational modeling has been 
extensively used to study this activity (Bolger et al., 1998, Irie et al., 2005).  Studies attempting 
to determine the distinct substrate specificities of PepT1 have revealed that almost all 
di/tripeptides constructed from physiological amino acids are potential substrates for transport 
(Vig et al., 2006).  While no similar study has been performed on PepT2, numerous peptides 
have been investigated as potential substrates and similar results have been obtained (Liu et al., 
1995, Ramamoorthy et al., 1995).  Both PepT1 and PepT2 have also demonstrated the capacity 
to transport compounds other than amino acids such as β-lactam antibiotics (Han et al., 1998, 
Terada et al., 1997), while PepT1 is also involved in the movement of bacterial peptides across 
the intestinal epithelium (Merlin et al., 1998).  This transport of non-physiological substrates is 
of interest as it provides another potential avenue for drug targeting, and it may be a causative 
factor in intestinal inflammation.  
1.2.1.1 Introduction to PepT1/PepT2 Structure/Function 
PepT1 consists of 12 trans-membrane domains (Figure 1), with each domain and loop 
unit associated with one of the 23 exons responsible for its coding (Urtti et al., 2001).  The 
transport of short peptides requires protons to provide a motive force, as well as sodium to 
maintain the proton gradient. NHE3, a sodium/proton antiporter, is responsible for providing the 
proton gradient necessary for intestinal PepT1 function (Ganapathy and Leibach, 1985).  PepT1 
has the capability to bind a large number of different substrates and the structure-affinity 
relationship of this transporter is an area of interest (Brandsch et al., 2004). With amino acids 
lengths of 710 and 729 respectively, PepT1 and PepT2 have several putative  
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Figure 1.1: Proposed structure of PepT1 
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phosphorylation and glycosylation sites.  Hydropathy analysis demonstrated that the peptide 
transporters likely contain 12 trans-membrane domains with cytosolic amino and carboxy 
termini (Fei et al., 1994).  In order to confirm the number and position of these trans-membrane 
domains, epitope mapping of human PepT1 was performed (Covitz et al., 1998).  This analysis 
confirmed the cytosolic location of the carboxy terminus and the number of trans-membrane 
domains.  Additionally, the experiment revealed that the loop between domains 3 and 4 was 
extracellular and a large extracellular loop between domains 9 and 10 was present.  The exact 
location of the amino terminus was not determined due to complications arising from epitope 
insertions between domains 1 and 3.  During these particular epitope insertions, hPepT1 function 
was disturbed, suggesting that this region is important for folding or transporter function.    
1.2.1.2 Recent Developments in the Structure of PepT1 
Although a large amount of data has been gathered through computational modeling and 
mutagenic studies, the structure of PepT1 is still under discussion.  Greater understanding of the 
protein structure, and thereby an understanding of substrate binding residues, would lead to 
predictions of binding affinity for novel therapeutic substrates.  Currently there is no complete 
structure of mammalian PepT1, however crystals structures have been obtained for numerous 
similar bacterial peptide transporters.   
Comparisons of PepT1 with the structure of LacY and GlpT, due to their predicted 
similarity in structure (Saier et al., 2006), aided in the development of a structural model of 
rabbit PepT1 (Meredith and Price, 2006).  This structural model was the first to directly 
challenge the hydropathy plot which predicted the 12 trans-membrane domains mentioned above 
(Fei et al., 1994).  Through the use of a more modern structural prediction program (MEMSAT3) 
(McGuffin et al., 2000), the predicted location of trans-membrane domain 1 shifted to residues 
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24 to 42 rather than 7 to 75, as predicted by hydropathy (Meredith and Price, 2006, Fei et al., 
1994).  This shift would provide an explanation for the complications found in the structural 
analysis via epitope mapping (Covitz et al., 1998).  The model proposed by Meredith and Price 
(2006) also positions a number of essential residues facing the central pore thereby providing a 
structural explanation for their importance.   
Recently the crystal structure of several prokaryotic peptide transporters has been solved 
(Newstead et al., 2011, Solcan et al., 2012, Doki et al., 2013).  PepTSo,  initially isolated from the 
bacterium Shewanella oneidensis, shares 30% identity within the trans-membrane regions of 
PepT1 and PepT2 including many of the previously identified significant residues (Newstead et 
al., 2011).  Unlike the previous models, PepTSo contains 14 trans-membrane domains at a 
resolution of 3.6 Å.  Transport of glycyl-sarcosine by PepTSo was similar to that of hPepT1 and 
experimentation with free amino acids, di/tripeptides and tetra-peptides suggested similar 
substrate affinity as other peptide transporters. Reliance on the proton motive force was also 
demonstrated in PepTSo.  Shortly after the publication of this structure the Newstead lab reported 
a higher resolution, 3.3 Å, structure of a peptide transporter from Streptococcus thermophilus,  
PepTSt (Solcan et al., 2012).  The functional characterization of this transporter revealed a hinge 
movement in the C-terminal region of the transporter, domains 10 and 11, with salt bridge 
interactions that alternate during the act of substrate transport.  The structure of a peptide 
transporter from Geobacillus kaustophilus (GkPOT) has been resolved at the highest resolution 
at1.9Å for ligand-free and 2.0 Å for sulphate bound form (Doki et al., 2013).  The structure of 
GkPOT was determined to be similar to that of PepTSo and PepTSt.  This was the first study to 
investigate the functional impact of site directed mutagenesis at this resolution.  Through the 
study of mutated forms of the protein it was shown that glutamate 310 is responsible for binding 
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the carboxyl group of the peptide substrate.  After substrate release, it is the interaction between 
glu310 and arg43 which causes a transition returning the transporter to a state ready to accept 
additional extracellular substrates. Although the determination of this structure is an important 
step in understanding the direct mechanism of action of peptide transport, it is important to 
consider that it only represents a static moment in the action of this transporter.  Since there is 
only a 30% identity between PepTSo and the mammalian PepT1 and PepT2, any direct 
comparisons on transport mechanisms or methods of substrate recognition must take this fact 
into consideration.   
1.2.1.3 Importance of Histidine, Arginine and Tyrosine Residues in Peptide Transport 
 Previous work has demonstrated that transport systems which co-transport hydrogen ions 
rely on histidyl residues for their activity (Ganapathy et al., 1987).  Considering that POT family 
members use these ions as the primary motive force, histidyl residues were studied as potentially 
vital components of both PepT1 (Kramer et al., 1988) and PepT2 (Miyamoto et al., 1986).  In 
order to specifically investigate the function of the histidyl residues, diethylpyrocarbonate 
(DEPC) was used in combination with brush-border membrane vesicles (BBMV) isolated from 
rabbit kidney (Miyamoto et al., 1986) or rabbit small intestine (Kramer et al., 1988).  The 
compound DEPC is capable of specifically altering the structure of histidine residues without 
modifying other residues in the protein.  The work by Miyamoto et al. (1986) demonstrated that 
functional histidyl residues were essential for PepT2 function, and suggested that thiol groups 
present around the binding site are also important.  They did not determine whether the histidine 
residues were present in the dipeptide-binding site or if they were involved with H
+
 binding.  
Treatment of BBMV with DEPC inhibited the transport of β-lactam antibiotics that contained an 
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-amino group, contributing to the theory that histidine residues are also important for PepT1 
function (Kramer et al., 1988). 
In order to understand the mechanisms controlling the binding capacity of these 
transporters, attention was directed towards the identification of specific histidine residues that 
were functionally significant.  Through sequence analysis it was determined that histidine 57 and 
121 were highly conserved in PepT1 and predicted to be present in trans-membrane domains 2 
and 4 respectively  (Terada et al., 1996).  Therefore site directed mutagenesis was performed 
replacing histidine 57, 121, or both, with glutamine and then measuring uptake of glycyl-
sarcosine, a hydrolysis resistant dipeptide, in Xenopus oocytes.  Alteration of either or both of 
these residues resulted in a dramatic reduction in glycyl-sarcosine transport, thereby indicating 
involvement in the activity of PepT1 through either substrate binding or other important 
functions.  Further research using a cell culture model transfected with either rat PepT1 or PepT2 
investigated the interaction of antibiotics with histidyl residues in an attempt to delineate the 
specific function of these residues (Terada et al., 1998).  It was established that the -amino 
group of both dipeptides and specific antibiotics interacted with the histidine residues; whether it 
was interaction with histidine 57 or 121 was unknown.  Study of these two residues has been 
ongoing, with certain results highlighting the significance of histidine 57 while suggesting that 
histidine121 is of little to no importance (Fei et al., 1997, Chen et al., 2000).  Other studies have 
maintained the necessity of two histidine residues, one for proton coupling and the other for 
peptide coupling (Steel et al., 1997).  
 Molecular and computational modelling of PepT1 has been very important in 
determining the potential importance of other conserved residues (Irie et al., 2005, Bolger et al., 
1998, Meredith and Price, 2006).  A positively charged amino acid residue, varying between 
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arginine or lysine depending on the animal being studied, is present in trans-membrane domain 7 
of all studied mammalian isoforms of PepT1 (Meredith, 2004).  There is a similar residue found 
in PepT2 indicating potential functional significance.  Investigation of the importance of arginine 
282 via mutagenesis into alanine slightly modified the uptake of glycyl-sarcosine in human 
embryonic kidney cells transfected with hPepT1 (Bolger et al., 1998).  Found in the seventh 
trans-membrane domain of PepT1 (Meredith and Boyd, 2000), mutation of this residue into 
glutamate uncoupled the transport of peptides from protons (Meredith, 2004).  This alteration 
from active to facilitated transport was investigated further in Xenopus oocytes transfected with 
wild-type and mutated rabbit PepT1 to determine the effect of the amino acid charge present at 
position 282 on transport of phenylalanyl-glutamine (Pieri et al., 2008).  Mutation of arginine 
282 to lysine, another positively charged amino acid, did not impact the efficacy of peptide 
transport.  Mutation of this position to histidine also exhibited similar activity as wild-type, 
potentially due to a positive charge on the histidine thus enabling it to function like arginine or 
lysine.  Double mutations revealed an interaction between arginine 282 with an aspartic acid 
residue at position 341 on trans-membrane domain 8 as charge swapping between these two 
residues (R282E/D341R) did not impact peptide transport.   
 A similar sequence of investigations has occurred with particular tyrosine residues in 
PepT1.  Beginning with sequence analysis, tyrosine 167 was identified as a conserved residue 
from bacteria to humans (Graul and Sadee, 1997).  Following its identification, tyrosine167 
underwent site-directed mutagenesis to alanine, phenylalanine, serine or histidine all of which 
abolished uptake of glycyl-sarcosine in cell culture (Yeung et al., 1998).  The sensitivity of 
transporter activity to the mutation of this residue, combined with the well conserved nature at 
this position, indicated the importance of this tyrosine residue.  Continued experimentation 
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revealed that tyrosine 56 is also important for peptide uptake as mutation to phenylalanine or 
alanine dramatically reduced transport of glycyl-leucine (Pieri et al., 2009, Chen et al., 2000).  
The tyrosine present at position 91was identified as potentially interacting with protons (Bolger 
et al., 1998) and mutation of that tyrosine reduced transport capacity (Links et al., 2007).  
Mutation of this residue uncoupled the transport of dipeptides from the proton motive force, 
strengthening the belief that tyrosine 91 was interacting with protons.  Further study has 
identified a potential interaction between tyrosine 91 and histidine 57, located adjacent to 
tyrosine 91 on trans-membrane domain 2 (Pieri et al., 2009).  As these residues are vital for 
proton coupling of peptide transport, this interaction may be involved in regulating pH 
stimulation of peptide transport   
1.3 PepT1 in the Intestine and Kidney 
1.3.1 Gastrointestinal Tract 
PepT1 was first discovered in intestinal samples (Erickson et al., 1995); thus, the 
gastrointestinal tract has undergone intense investigation to determine the distribution of this 
peptide transporter.  Most studies have reported no detection of PepT1 in the oesophagus, 
stomach, cecum or rectum (Ogihara et al., 1996, Freeman et al., 1995); however, one study 
detected weak expression of PepT1 mRNA in the stomach of rodents (Lu and Klaassen, 2006).  
In the intestine, the transporter is localized to the apical membrane of the villi, facilitating access 
to digesta passing through the lumen (Ogihara et al., 1996).  Both PepT1 protein and mRNA 
have been detected in the small intestine of a variety of animal species and the concentration of 
the transporter varies depending on intestinal location and species studied.  Black bears showed 
the highest concentration of PepT1 in the middle of the small intestine (Gilbert et al., 2007b) 
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while studies in humans have demonstrated the greatest presence in the duodenum/jejunum 
(Terada et al., 2005, Herrera-Ruiz et al., 2001).  In contrast, Chen et al. showed a consistent 
amount of PepT1 expression across the entire length of the small intestine of mature sheep, dairy 
cows, pigs, and chickens (Chen et al., 1999).  A study performed in 8-week old rats and mice 
showed no significant differences in the amount of PepT1 mRNA along the length of the small 
intestine (Lu and Klaassen, 2006).  Developmental changes in the location and concentration of 
PepT1 along the small intestine have been reported in rats (Shen et al., 2001), chickens (Chen et 
al., 2005) and pigs (Wang et al., 2009).  Shen et al. (2001) reported that PepT1 presence in the 
colon was transient; by day seven no PepT1 mRNA was found in the colon of developing rats.  
PepT1 has been found in the colon of rats at later time points (Shi et al., 2006a), but its presence 
has been primarily related to a state of intestinal injury such as gut resection and therefore has 
been a source of controversy.  A study in rats demonstrated increased PepT1 protein in the colon 
of animals with intestinal resection that were fed chow (Shi et al., 2006a), whereas rats fed an 
elemental diet did not express any PepT1 mRNA in colonic tissues (Lardy et al., 2006).  A recent 
study demonstrated that there is a greater concentration of PepT1 mRNA in the distal colon of 
mice, rather than proximal, and that this signal was lost in PepT1 knockout mice (Wuensch et al., 
2013).  Assessment of glycyl-sarcosine transport combined with immunofluorescence indicated 
that PepT1 protein was present in the distal colon of wild-type mice and that it was fully 
functional.  A similar condition has been demonstrated in humans, as PepT1 has been detected in 
the colon of humans that have undergone intestinal resection (Ziegler et al., 2002).  When 
compared to control subjects, PepT1 mRNA and protein isolated from colonic samples were 
higher in patients with massive bowel resections.   When combined, these distribution patterns 
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indicate that while PepT1 is ubiquitously expressed in the small intestine of numerous animals, 
colonic PepT1 is only present in early life or in disease states.   
1.3.2 Kidney 
Although PepT2 is considered to be the primary peptide transporter in the kidney, 
expression profiling of the kidney has revealed the presence of both PepT1 and PepT2 (Lu and 
Klaassen, 2006, Smith et al., 1998, Shen et al., 2001).  Analysis of specific regions of rat kidney 
revealed that there is a gradient of expression, from proximal to distal nephron, in both PepT1 
and PepT2 (Smith et al., 1998).  PepT1 was found solely in the kidney cortex with PepT2 being 
expressed in the cortex and the medulla.  While PepT2 was more abundant in rat kidney 
compared to PepT1, the latter was more specific for the early segments of the proximal tubule, 
S1, with the former having a greater concentration in the later segments, S2 and S3.  This, when 
combined with the low-affinity/high-capacity aspect of PepT1 and the high-affinity/low-capacity 
aspect of PepT2, indicates that the reabsorption of peptides in the kidney is handled in a 
sequential manner.  It has been suggested that PepT2 is primarily responsible for the transport of 
peptides, as glycyl-sarcosine was reabsorbed from the late portions of the proximal tubule 
(Silbernagl et al., 1987).  The relative importance of PepT1 in renal peptide transport has yet to 
be determined; however as it is a high-capacity transporter its role may be significant. 
1.4 Regulation of PepT1 in Health and Disease 
1.4.1 Dietary Factors 
There is a growing body of evidence demonstrating that PepT1 expression and activity is 
at least partially substrate driven.  Rats fed a high protein diet had greater uptake of carnosine 
than rats fed a low protein diet (Ferraris et al., 1988).  As carnosine is a substrate for PepT1, this 
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result suggested that diet may play a role in regulating PepT1; however the mechanism had yet to 
be determined.  Although the transporter was identified along the length of the small intestine, a 
high protein diet fed to rats induced PepT1 transcription in the proximal small intestine only 
(Erickson et al., 1995).  Greater abundance of PepT1 transporters was also observed in rats fed a 
standard diet supplemented with a single dipeptide compared to controls fed free amino acids 
(Shiraga et al., 1999).  The quality of protein ingested may also affect PepT1 expression.  A 
study performed in broiler chicks investigated whether PepT1 expression differed if corn-based 
diets were supplemented with soybean meal or gluten meal (Gilbert et al., 2008a).  Chicks fed 
soybean meal had greater expression of PepT1 than those fed gluten, similar to the trend found in 
the b
o,+
 AT, a neutral and basic free amino acid transporter.  Incubation of Caco-2 cells with a 
dipeptide resulted in alteration of the expression of PepT1 (Walker et al., 1998).  Caco-2 cells 
were transfected with human PepT1 cDNA and incubated with the dipeptide glycyl-glutamine.  
This dipeptide exposure increased transport of glycyl-sarcosine with increased expression of 
PepT1 mRNA and a concomitant increase in PepT1 protein.   
  Increasing evidence suggests that PepT1 expression and/or activity can be altered by 
manipulating nutritional status or health. In situations of gut stress such as malnutrition, 
intestinal failure or surgical intervention, PepT1 expression is maintained or increased, in 
contrast with other nutrient transporters which typically decline in number (Satoh et al., 2003).  
Humans fasted for 14 days demonstrated a significant decrease in the transport of amino acids 
but peptide transport was maintained (Vazquez et al., 1985). Changes were described in the 
transporter population in rats that were either food deprived for 4 days, food restricted to 50% of 
a control group intake, or nourished completely by parenteral nutrition (PN) (Ihara et al., 2000).  
The food deprived rats demonstrated an increase in PepT1 mRNA in the proximal gut by 179% 
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compared to controls.  The PN-fed rats with atrophy of the small intestine (SI) responded 
similarly to the food deprived animals.  Similar responses were observed in broiler chicks 
undergoing feed restriction (Chen et al., 2005, Gilbert et al., 2008a).  In one study, chickens were 
assigned to diets containing 12, 18 or 24 % crude protein  with sampling performed  during the 
first 35 days post-hatch (Chen et al., 2005).  Dietary intake of chickens receiving 18% or 24% 
crude protein (CP) was restricted to that consumed by those receiving the 12% diet with an 
additional group receiving free access to the 24% CP diet.  Chickens on 12% CP showed lower 
expression of PepT1, but the animals receiving a higher protein diet but restricted intake had 
higher expression of PepT1 compared to those receiving unlimited access to the higher protein 
diet.  Animals with free access to the diet containing 24% CP had declining expression of PepT1 
mRNA during the first two weeks of the study with increasing expression afterwards; however 
animals undergoing diet restriction still had greater expression of PepT1. Interestingly, high 
luminal concentrations of some free amino acids may impair dipeptide uptake (Himukai et al., 
1982), although this finding varies between in vitro model systems (Daniel, 2004).   This 
suggests that dietary factors, such as protein content in the diet, alter the expression of PepT1. 
1.4.2 Development 
Differences in the location and concentration of PepT1 mRNA along the small intestine 
during development have been reported in rats (Shen et al., 2001), chickens (Chen et al., 2005, 
Gilbert et al., 2007a) and pigs (Wang et al., 2009).  In rats, there is a dramatic shift in cellular 
localization of PepT1 between 18 days gestation and immediately after birth at 21 days gestation 
(Hussain et al., 2002).  Following birth there is a movement of PepT1 protein from the brush 
border membrane of the enterocytes to the cytoplasm and the basolateral membrane.  The 
transient nature and functional importance of this basolateral Pept1 has yet to be elucidated.  
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Early work on the developmental changes in rats showed that intestinal PepT1 mRNA was 
highest at 4 days of age and continued to decline until reaching concentrations found in 
adulthood at 28 days of age (Miyamoto et al., 1996).  Similarly, Shen et al. (2001) demonstrated 
that although PepT1 mRNA expression was at its highest point 3-5 days after birth in a neonatal 
rat model, it declined rapidly at all locations in the small intestine during the suckling period.  
Comparable to rats, chickens also demonstrated variance in the location and concentration of 
PepT1 mRNA during development (Chen et al., 2005, Gilbert et al., 2007a).  In a study of 
broilers, chickens raised for meat production,  PepT1 mRNA increased linearly with age (Chen 
et al., 2005).  Further investigation into the differences among intestinal positions corroborated 
this result and revealed that the greatest expression of PepT1 mRNA was found in the duodenum 
(Gilbert et al., 2007a).  Microarray analysis has been performed on chicken intestinal samples 
taken at varying stages of development from late stage embryos to two weeks post-hatch (Li et 
al., 2008).  In agreement with the previous studies, there was a linear increase in PepT1 mRNA 
in all regions of the chick intestine sampled from embryonic day 18 to post-hatch day 20 and at a 
greater quantity in the duodenum and jejunum compared to the ileum.  In Tibetan piglets, PepT1 
mRNA increased in the duodenum and jejunum from birth to the middle of the suckling period, 
after which the expression decreased in these intestinal regions (Wang et al., 2009).  In these 
animals the distal jejunum had greater expression of PepT1 mRNA than the other intestinal 
regions tested.  D’Inca et al. determined that there was a dramatic decrease in piglet PepT1 
mRNA expression within the first 48 hours after birth; however, intrauterine growth restriction 
delayed this adaptation (D'Inca et al., 2011). This suggests that PepT1 and peptide transport are 
potentially important in the early life of the suckling neonate.   
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1.4.3 Insulin 
Insulin is a key metabolic regulatory hormone that has been demonstrated to regulate 
amino acid transport.  Incubation with insulin was shown to rapidly increase dipeptide transport 
in a Caco-2 cell line (Thamotharan et al., 1999).  Inclusion of genistein, an inhibitor of receptor 
tyrosine kinases, in the incubation medium prevented this transport increase thereby 
demonstrating that the effect was due to insulin signalling.  A shift in the Vmax of PepT1 
confirmed an increase in the transporter population rather than an effect on substrate affinity.  
Curiously, a concomitant increase in PepT1 protein without an increase in PepT1 mRNA was 
observed.  Disturbance of the Golgi apparatus by brefeldin treatment did not disrupt the effect of 
insulin, while depolymerizing the microtubules through colchicine treatment abolished the 
increase in peptide uptake.  This indicated that insulin was inducing the movement of a pre-
existing cytosolic pool of PepT1 to the apical surface, rather than de novo transporter synthesis.  
A study on the impact of insulin treatment on the transport of cephalexin (an antibiotic substrate 
of PepT1) in Caco-2 cells co-incubated with genistein and/or colchicine had similar results 
(Watanabe et al., 2004). Taken together, it is possible that circulating insulin interacts with 
receptors on the basolateral membrane of enterocytes to mobilize cytosolic stores of PepT1 to the 
apical membrane thereby facilitating increased uptake of substrates present in the intestinal 
lumen.  This was confirmed by studies in Caco-2 cells (Nielsen et al., 2003).  Similar to previous 
studies, brefeldin and colchicine inhibited the insulin stimulated uptake of the test dipeptide, in 
this case glycyl-sarcosine.  Basolateral stimulation of Caco-2 cells with insulin resulted in greater 
uptake of glycyl-sarcosine than either control or apical stimulation, with no difference detected 
between apical stimulation and control samples.   
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1.4.4 Short Bowel Syndrome 
Short bowel syndrome (SBS) is a clinical condition induced through the surgical removal 
of intestinal tissue.  Causes for intestinal resection are varied and include inflammatory disorders 
such as Crohn’s disease and colitis, tumors, physical trauma and infection such as necrotizing 
enterocolitis (NEC) (Goulet et al., 1991).  Intestinal resection results in a loss of absorptive 
capacity (Sukhotnik et al., 2002) potentially leading to a requirement for long term parenteral 
nutrition.  In newborn and pre-term infants, SBS is commonly the result of congenital 
malformations or necrotizing enterocolitis (Sodhi et al., 2008).  NEC is an aggressive, anaerobic 
infection that develops rapidly in the gastrointestinal tract in approximately 10% of all very low 
birth weight infants, with up to a 34% mortality rate in the lowest birth weight category 
(Fitzgibbons et al., 2009).  If SBS occurs as a consequence of intestinal disease, then a number of  
strategies have been employed in an attempt to improve nutrient absorption, intestinal  motility 
and subsequently, adaptation (Miller and Burjonrappa, 2013).  Elucidation of adaptive responses 
after intestinal resection, including alteration in peptide transport, could lead to dietary 
treatments that are designed to optimize nutrient availability in the compromised SI, and 
ultimately enhance adaptation in the remaining intestine. 
1.4.5 PepT1 and Intestinal Adaptation in SBS 
Whether or not PepT1 expression occurs in the colon after short bowel surgery is 
controversial.  After an 80% small intestinal resection in rats, changes were quantified in the 
colon one week post-operatively (Lardy et al., 2006).  There was no difference in PepT1 
expression compared to controls; however, this may have been due to the post-resection feeding 
of an elemental diet, which did not provide the stimulus necessary to induce the transporter.  In 
contrast, Shi et al. (2006a) developed a rat model that used SI resection in rats to induce colonic 
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PepT1 (Shi et al., 2006a).  This resected rat model was used to study the role of PepT1 in colonic 
inflammation.  This study clearly identified PepT1 protein in the colon of SI resected but not 
control rats, when killed 2 weeks post-operatively.  Rats were fed a liquid diet initially, and rat 
chow for the final week.  Therefore the induction of PepT1 in the colon may require the luminal 
presence of dipeptides.  One study investigated whether colonic PepT1 was expressed in patients 
with SBS (Ziegler et al., 2002).  Mucosal biopsy specimens were obtained from 13 adult patients 
with SBS and 33 controls.  There was no difference in PepT1 expression in the ileum of SBS 
patients compared to controls; however, there was a fivefold higher expression of the transporter 
in samples from the colon of SBS patients.  Although there has been much research on colonic 
adaptation, currently no study has investigated the impact of enterally delivered dipeptides on 
small intestinal adaptation in a piglet model of short bowel syndrome.   
1.4.6 Inflammatory Bowel Disease 
Inflammatory bowel disease (IBD) is an umbrella term used to describe chronic 
inflammation of the large and/or small intestine.  Although there are many types of inflammatory 
bowel diseases the most prominent, and most extensively studied, are Crohn’s disease and 
ulcerative colitis (Baumgart and Sandborn, 2012).  Crohn’s disease was first described in 
patients suffering inflammation of the ileum, but inflammation can be found in any area of the 
gastrointestinal tract including the colon.  Ulcerative colitis, however, is an intermittent disease 
where inflammation occurs primarily in colonic tissue.  In humans, colonic expression of PepT1 
has been reported in patients with inflammatory bowel disease (Merlin et al., 2001).  Evidence 
from both human and rat studies has indicated that PepT1 is capable of transporting of bacterial 
peptides, which may exacerbate the inflammatory process in Crohn’s disease and ulcerative 
colitis (Merlin et al., 2001, Shi et al., 2006c). Initial studies in Caco2-BBE cells, a variant of the 
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Caco2 cell line with greater homogeneity of brush border proteins,  demonstrated both the 
presence of human isoform of PepT1 and its capacity to transport the bacterial peptide formyl-
methionyl-leucyl-phenylalanine (fMLP) (Merlin et al., 1998).  Further investigation revealed that 
hPepT1 is expressed in the colon of patients with chronic ulcerative colitis, but not normal 
colonic tissue, and that transport of fMLP may affect immune response by stimulating expression 
of MHC-1 molecules (Merlin et al., 2001). One theory suggests that in IBD, there is an over 
production of proinflammatory peptides by the colonic microflora.  These peptides then act as 
substrates to induce PepT1 expression in the colon (Adibi, 2003). Exploration of the interaction 
between PepT1, bacteria and the immune system may result in a greater understanding of 
peptides in the intestinal inflammatory response. 
1.5 Substrates for PepT1 
1.5.1 Di/tripeptides 
To understand the potential impact of peptide transport, it is important to consider the 
variable affinity of PepT1 substrates.  Alanyl-alanine, for example, has a high affinity for PepT1 
(Ki of 0.08 mM) whereas glycyl-sarcosine is classified as a medium affinity substrate with a Ki 
of 1.1 mM, determined in Caco-2 cells (Brandsch et al., 1999, Brandsch et al., 1998).  Other 
sarcosine containing dipeptides have Ki’s ranging from 0.13 mM for phenylalanyl-sarcosine to 
2.5 mM for sarcosyl-proline, with sarcosyl-sarcosine showing no affinity for PepT1 (Brandsch et 
al., 1999).  Another study has reported an apparent Ki for sarcosyl-sarcosine as 15.9 mM; 
however affinities higher than 15 mM are typically considered to be non-substrates (Daniel et al., 
1992). 
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Dipeptides containing proline, in either the N-terminal or C-terminal position have been 
extensively studied in both kidney BBMV and Caco-2 cells (Thwaites et al., 1994, Daniel et al., 
1992, Brandsch et al., 1999).  In the case of prolyl-glycine, transport was undetectable in the 
kidney (Daniel et al., 1992) while an excess of the dipeptide reduced the uptake of glycyl-
sarcosine by only 59% in Caco-2 cells (Thwaites et al., 1994).  In an investigation of the 
transport of twelve different X-pro dipeptides in Caco-2 cells, all dipeptides were able to reduce 
uptake of glycyl-sarcosine (Brandsch et al., 1999).  Affinity for PepT1 ranged from 0.15 mM for 
alanyl-proline to 1.2 mM for prolyl-proline.  A concurrent experiment was performed by 
replacing the C-terminal proline with alanine, for example alanyl-proline would become alanyl-
alanine.  Interestingly, most X-ala dipeptides investigated showed greater affinity for PepT1 than 
X-pro, with the exception of prolyl-alanine which had a Ki of 9.5 mM compared to the 1.2 mM 
of prolyl-proline.  This investigation determined that in the case of X-pro dipeptides, the affinity 
for PepT1 is positively correlated with the percentage of trans conformation present, with greater 
cis conformation reducing transporter affinity.   
 In recent years it was suggested that Ki ranges should be used to describe PepT1 
substrates as high affinity (Ki <0.5 mM), medium affinity (Ki 0.5-5 mM) and low affinity (Ki >5 
mM) with non-substrates having an affinity > 15 mM (Brandsch et al., 2004).  This would enable 
easier classification of PepT1 substrates and potentially reduce the variability currently in the 
literature pertaining to affinity, as literature Ki values are inconsistent.  The most thorough 
investigation into dipeptide transport to date was published in 2006 (Vig et al., 2006).  This study 
quantified the IC50, the half maximal inhibitory concentration, of 81 different di/tripeptides in 
MDCK cells expressing hPepT1.  Although IC50 is not directly indicative of the Ki, the two are 
related where the lower the IC50 the greater the affinity of the substrate for the transporter of 
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interest.  Similar to the classification system proposed by Brandsch et al. (2004), the study by 
Vig et al. (2006) attempted to group the substrates investigated as either non/poor, intermediate, 
good or best substrates for PepT1.  In this system the best substrates for PepT1 include ala-ala, 
ala-phe, ala-tyr, leu-leu, phe-ala, phe-gly, phe-phe, phe-tyr, trp-ala, trp-val, tyr-ala, tyr-tyr, and 
val-val.  In contrast, certain dipeptides tested were not substrates for PepT1. This challenges the 
long held theory that all di/tripeptides are substrates for PepT1. These studies centering on the 
elucidation of peptide affinities provide indirect evidence regarding the binding pockets present 
in PepT1 thereby providing important information regarding the structure of this transporter. 
1.5.2 Bacterial peptides 
Bacterial colonization is more prolific in the colon than the small intestine.  Certain 
bacterial peptides are substrates for PepT1, two examples of which are formyl-methionyl-leucyl-
phenylalanine (Shi et al., 2006c, Carlson et al., 2007, Buyse et al., 2001) and l-Ala--d-Glu-
meso-DAP, Tri-DAP (Dalmasso et al., 2010).  Escherichia coli produces chemotactic 
compounds, however the major neutrophil chemotactic substance produced is formyl-methionyl-
leucyl-phenylalanine (fMLP) (Marasco et al., 1984).  Transport of fMLP by PepT1 has been 
demonstrated in cell culture (Merlin et al., 1998) and in rats (Buyse et al., 2002, Shi et al., 
2006a).  In Caco-2 cells, uptake of fMLP was inhibited by the presence of known substrates of 
PepT1 (Merlin et al., 1998, Foster and Zheng, 2007).  Creation of an inwardly directed proton 
gradient increased the uptake of fMLP in this model, thereby providing further support that 
PepT1 is responsible for the transport of this peptide. Transport of fMLP was shown to induce 
neutrophil migration across the epithelial monolayer, an activity which was abolished if fMLP 
uptake was inhibited.  Transport of fMLP has also been measured in rats using intestinal 
perfusion (Buyse et al., 2002).  Differences in the inflammatory response to fMLP were found 
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based on gut location.  Perfusion of fMLP in the jejunum, where there is a high expression of 
PepT1, resulted in neutrophil invasion and altered morphology while colonic perfusion produced 
no indices of inflammation.  Perfusion of fMLP into the colon of rats with SI resection (the 
model used to up-regulate PepT1 expression in the colon) resulted in greater myeloperoxidase 
activity and damage to the colonic mucosa compared to controls (Shi et al., 2006a, Shi et al., 
2006c).  The mechanism by which fMLP can induce a pro-inflammatory cytokine response is 
through the interaction with TNF- leading to an increase in NFκβ (Pan et al., 2010, Pan et al., 
2000).  It is through this signalling cascade that fMLP is able to induce intestinal inflammation.  
As PepT1 expression is negligible in a healthy colon, bacterially produced peptides have little 
access to this transporter which minimizes the potential for transport.  Abnormal expression of 
Pept1 in the colon, overgrowth of bacteria in the small intestine or increased intestinal 
permeability due to atrophy provide opportunities for transport or translocation of bacterial 
peptides.  Competitive inhibition or direct regulation of PepT1 expression may ameliorate 
intestinal inflammation in cases of excessive bacterial peptide exposure to PepT1.  To date there 
have been no studies quantifying the effect of fMLP in a state of intestinal atrophy. 
1.5.3 Cysteinyl-glycine 
Cysteine is a conditionally essential amino acid in neonates.  It can be synthesized via 
trans-sulfuration from methionine; however, cysteine is classified as conditionally essential as 
adequate methionine is necessary to support cysteine synthesis.  Additionally, there is evidence 
that the enzyme cystathionase, which is  involved in cysteine synthesis (Rao et al., 1990), is 
immature in preterm infants and cannot supply sufficient cysteine to meet whole body 
requirements (Zlotkin and Anderson, 1982) if dietary cysteine is inadequate.  Cysteine is a 
component of proteins and is also precursor for taurine and glutathione synthesis, both of which 
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function as antioxidants (Beetsch and Olson, 1998).  Rapid cell growth and turnover, and 
maintenance of the redox status in the mucosa are both vital to maintenance of the integrity of 
the intestinal barrier.  As such, adequate cysteine availability is important to the intestine. This 
was demonstrated in a study during which piglets were fed an enteral diet free of sulfur amino 
acids (Bauchart-Thevret et al., 2009).  The authors reported reduced cellular proliferation, lower 
numbers of goblet cells and reduced villus height in the small intestine.  Given that it was a diet 
free of methionine, protein synthesis was reduced leading to intestinal atrophy.  Further, with the 
absence of dietary methionine, cysteine could not be synthesized.  Cysteine is necessary for 
protein synthesis, but also has been shown to have direct stimulatory effects on cellular 
proliferation, via influencing the movement from the G1 to S phase of the cell cycle (Noda et al., 
2002).  Thus, a deficit in sulfur amino acids in the intestinal mucosa has profound multifactorial 
effects on growth and proliferation.  Cysteine alone is part of the oxidative stress control system 
(Jones, 2006); however, it is also a residue in the tri-peptide glutathione (-Glu-Cys-Gly, GSH) 
which contributes to controlling cellular redox states (Wu et al., 2004).  Limiting the availability 
of cysteine led to lower concentrations of glutathione in the plasma and intestinal mucosa of rats 
(Nkabyo et al., 2006).  Conversely, when diets were supplemented with sulfur amino acids 
(218% of requirement), rats had greater plasma redox potential.  Studies in humans with 
inflammatory bowel disorders requiring surgical resection have demonstrated compromised 
redox status  thereby influencing cellular signalling/metabolism and potentially aiding in the 
development of inflammation (Sido et al., 1998).   
Cysteinyl-glycine (CG) is a product of glutathione degradation (Cappiello et al., 2004) 
that can be hydrolyzed by a number of different peptidases; however, the stability of the 
dipeptide in plasma has not been as clearly delineated (Cappiello et al., 2004).  Although there 
25 
 
have been no studies specifically investigating whether CG is a substrate for PepT1, certain 
characteristics of dipeptides can be used to determine their affinity for transport via PepT1.  A 
study involving a variety of small peptides detailed the effect of peptide size, hydrophobicity, 
composition and charge on dipeptide transport (Vig et al., 2006).  Cysteine containing dipeptides 
were not tested in that study, but the results can be used to make inferences regarding the 
bioavailability of cysteinyl-glycine. All X-gly dipeptides were transported via PepT1 and neutral 
dipeptides resulted in higher activation than charged peptides thereby suggesting that CG is a 
viable substrate for PepT1.  An investigation of peptide transport in astroglia-rich primary 
cultures, a cell type containing PepT2, demonstrated that the uptake of CG was inhibited in the 
presence of alanyl-alanine, a known substrate for both PepT1 and PepT2 (Dringen et al., 1998).  
This result supports the theory that cysteinyl-glycine is a substrate for PepT1.  For individuals 
with compromised SI function, the inclusion of cysteine-containing peptides in enteral diets may 
enhance cysteine availability due to the stability of PepT1 expression and efficiency of peptide 
transport.  Improved cysteine availability may, in turn, enhance cellular proliferation and/or the 
generation of GSH, leading to greater redox capability and better recovery of the injured gut. 
1.5.4 Alanyl-glutamine 
One of the more clinically studied dietary substrates of PepT1 is the glutamine-containing 
dipeptide alanyl-glutamine (AQ).  There are known physiological benefits when glutamine is 
provided as a dipeptide rather than its free amino acid form.  Glutamine is much more stable as a 
dipeptide, and the concentration of plasma glutamine was greater when glutamine was provided 
to healthy men as alanyl-glutamine versus L-glutamine (Harris et al., 2012).  The impact of this 
dipeptide on intestinal health has been studied in vitro using cell culture (Alteheld et al., 2005) 
and in vivo via PN infusion into piglets (Burrin et al., 1994); as well, a number of human trials 
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have employed both enteral and parenteral provision of this dipeptide (Eroglu, 2009, Luo et al., 
2008, Lima et al., 2007).  Parenteral provision of AQ has been shown to increase antioxidant 
capacity and plasma glutamine concentrations, while intraperitoneal injection of AQ reduced the 
number of IFN- producing cells in a mouse model of dextran sodium sulfate-induced colitis 
(Chu et al., 2012).   A comparative study of enteral versus parenteral alanyl-glutamine in 
critically ill patients revealed that plasma glutamine was higher when the dipeptide was provided 
parenterally (Luo et al., 2008).  Other studies determining organ specific removal of dipeptides 
from human plasma observed that the liver, kidneys, muscle and intestine were responsible for 
removing 60% of the plasma alanyl-glutamine (Vazquez et al., 1993).  When provided as the free 
amino acid, enteral glutamine supressed pro-inflammatory cytokine production during an E. coli 
challenge in piglets (Ewaschuk et al., 2011); however the beneficial effect of enteral glutamine-
containing dipeptides has yet to be determined (Luo et al., 2008, Eroglu, 2009, Ligthart-Melis et 
al., 2009).  Greater understanding of the potential beneficial or harmful effects of enterally 
provided glutamine peptides such as alanyl-glutamine would provide the basis for more effective 
delivery of glutamine in situations where regular intestinal function is compromised.  
1.6 Intestinal immune system and cytokine response 
1.6.1 Epithelial barrier  
One of the roles of the epithelium of the small intestine, outside of nutrient transport, is to 
act as a barrier between the contents of the lumen and the circulatory system.  In a healthy 
individual the intestinal barrier is intact, preventing both paracellular transport of foreign or 
infectious material and interaction of luminal bacteria with the intestinal cells (Turner, 2009).  In 
cases of intestinal inflammation this barrier function of the intestine fails, leading to the 
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recruitment of immune cells and the propagation of the inflammatory response (Groschwitz and 
Hogan, 2009).  A multifaceted defense, the intestinal barrier is comprised of both extracellular 
and intracellular components.   
The most notable part of the extracellular barrier is the protein family known as mucins 
(McGuckin et al., 2009).  Mucins, produced by goblet cells, are heavily glycosylated proteins 
which have multiple functions including the prevention of direct bacterial contact with 
enterocytes (Johansson et al., 2008).  The thickness of the mucin layer varies depending on 
intestinal location, but has been found to be upwards of 800 µm thick in the colon of rats (Atuma 
et al., 2001).  Besides reducing bacterial contact with the epithelium, this mucous layer also 
contains a number of antimicrobial compounds including immunoglobulins, lectins and 
antimicrobial peptides such as defensins and cathelicidins (McGuckinet al., 2009).  These 
antimicrobials can be maintained at a much higher concentration by being present in the mucous 
layer than if they were secreted directly into the lumen of the intestine, thereby increasing their 
efficacy.  
The intercellular component of the intestinal barrier involves regulation of paracellular 
transport.  The apical junction complex is comprised of the tight junction proteins including 
claudins and occludins, and the adherens junction, involving E-cadherin and catenins (Laukoetter 
et al., 2006). This complex regulates the movement of solutes, and bacteria, through the 
paracellular pathway.  Any disruption of the apical junction complex results in a reduction of 
epithelial barrier integrity, increasing the risk of infection and inflammation.   In addition to the 
epithelial barrier provided by the enterocytes, the lymphoid tissue found within the intestine 
provides a wide range of immune cells, and biochemical signals, responsible for aiding in the 
prevention of infection and disease. 
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1.6.2 Mucosa-associated lymphoid tissue 
The mucosa-associated lymphoid tissues comprise the largest immune organ in the body 
(Turner, 2009); however there are site-specific differences between the various mucosal surfaces 
in the body.  Gut-associated lymphoid tissue is comprised of Peyer’s patches, organized 
lymphoid nodules, and mesenteric lymph nodes (Wershil and Furuta, 2008).  Peyer’s patches are 
found underneath a specific layer of columnar cells referred to as the follicle associated 
epithelium which contains a specialized epithelial cell type known as a microfold or M cell 
(Neutra, 1999).  The function of these M cells is to transport antigens from the lumen of the 
intestine directly to the lymphoid tissues and present them to dendritic cells.  Another method of 
inducing the immune response in the intestine occurs solely through dendritic cells, without the 
assistance of M cells (Rescigno, 2010).  Certain classes of dendritic cells are capable of sampling 
the contents of the intestinal lumen directly thereby obtaining antigens to present to naïve T-cells 
and B-cells resulting in their activation. Whether through the action of M cells or through 
dendritic cells alone, presentation of the foreign antigen is the first step in the initiation of the 
immune response, which can act through signalling compounds known as cytokines. 
1.6.3 Pro-inflammatory and anti-inflammatory cytokines 
1.6.3.1 TNF-α 
Tumor necrosis factor α (TNF-α) is a potent pro-inflammatory cytokine that plays a vital 
role in chronic inflammatory diseases such inflammatory bowel disease (Pedersen et al., 2014) 
but is also involved in the inflammatory response to infection (Surbatovic et al., 2013).  The 
primary cell type responsible for the production of TNF-α is activated macrophages, a subset of 
macrophages that have been exposed to interferon-γ in combination with either TNF-α or an 
infectious agent such as bacteria (Mosser, 2003).  It is important to note that while macrophages 
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are the primary producers of TNF-α, lymphocytes, as well as other cell types such as mast cells 
and neutrophils, are also capable of producing TNF-α albeit to a lesser extent (Kriegler et al., 
1988, Luettig et al., 1989). 
Initially TNF-α is produced as a 26 kDa transmembrane protein that is capable of acting 
as a ligand, interacting with TNF-α receptors directly, or as a receptor by transmitting 
extracellular information into the cell (Eissner et al., 2004). This transmembrane TNF-α can then 
be acted upon by a TNF-α converting enzyme to release a 17 kDa product, the soluble form of 
TNF-α (Black et al., 1997).  Both the transmembrane and soluble forms of TNF-α are 
homotrimers and this trimeric structure is required in order to mediate the biological activity of 
this cytokine (Tang et al., 1996).   
 There are two primary receptors for TNF-α, TNF-R1 and TNF-R2 (Hohmann et al., 
1989) however these receptors are regulated via different mechanisms (Vandenabeele et al., 
1995).  Expression of TNF-R1 is regulated by a house-keeping promoter that cannot be 
stimulated by other cytokines such as TNF-α or IFN-γ (Rothe et al., 1993). The regulation of 
TNF-R2 is more complex and differs based on cell type.  Macrophages, for example, show 
increased expression of TNF-R2 after exposure to bacterial products such a lipopolysaccharide 
(Tannenbaum et al., 1993) whereas B-cells require exposure to mitogens in order to begin 
increasing expression of this receptor (Erikstein et al., 1991).  While the extracellular portion of 
the TNF-α receptors are very similar, the intracellular domains show little sequence homology 
indicating significantly different methods of action (Ledgerwood et al., 1999). 
Capable of being activated by both the membrane bound and soluble forms of TNF-α, the 
signalling pathway of TNFR-1 is both well characterized and intricate (Grell et al., 1995).  After 
activation, TNFR-1 is bound by the TNF-receptor associated death domain protein which then 
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activates either the pro-apoptotic pathway, via the FAS-associated death domain protein, or the 
pro-inflammatory pathway via TNF receptor-associated factor 2 (TRAF2) and activation of 
NFκβ (Ting et al., 1996).  Unlike TNFR-1, TNFR-2 is only able to be activated via the 
transmembrane form of TNF-α (Grellet al., 1995).  Interestingly TNFR-2 is capable of inducing 
most of the same signalling pathways as TNFR1, despite the differences between their 
cytoplasmic domains (Rothe et al., 1994).  Unlike TNFR-1, TNFR-2 lacks the death domain 
binding capability and so the primary signalling route is through the TRAF2 pathway; the 
pathway which results in the activation of NFκβ.  
1.6.3.2 Interferon-γ  
Interferon-γ (IFN-γ) is a vital component of the innate and adaptive immune responses.  
This cytokine is involved in defending against infections (Filipe-Santos et al., 2006), viral 
diseases (Sedger et al., 1999), and tumor prevention (Ikeda et al., 2002).  In the innate immune 
response, the primary cells responsible for the production of IFN-γ are the natural killer cells, a 
type of cytotoxic lymphocyte, and natural killer T cells, a group of cells sharing the properties of 
both T cells and natural killer cells (Stetson et al., 2003).  These cell types are able to respond to 
infection through the rapid production of IFN-γ.  In the adaptive immune system the CD8+ 
cytotoxic lymphocytes and CD4
+
 Th1 effector T cells are capable of producing IFN-γ however 
this process takes several days (Bach et al., 1997). 
The membrane bound IFN-γ receptor is comprised of two primary components, the 
ligand binding IFN-γ R1 chain, 90 kDa, and the accessory IFN-γ R2 chain, 60 kDa, both of 
which contain extracellular and cytosolic domains (Pestka et al., 1997).  Binding of IFN-γ to its 
receptor requires dimerization of the cytokine (Ealick et al., 1991), while transduction of the 
appropriate signals into the cell requires four subunits, two each of the R1 and R2 chains 
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(Pestkaet al., 1997).  If only IFN-γ R1 is present, signal transduction does not occur (Rashidbaigi 
et al., 1986) and without IFN-γ R1, the R2 chain is unable to crosslink or bind IFN-γ (Kotenko et 
al., 1995).  Signal transduction through the IFN-γ receptor complex also requires the recruitment 
of kinases. The intracellular domain of IFN-γR1 contains the binding motifs necessary for the 
recruitment of Janus tyrosine kinase (JAK) 1 as well as the recruitment of signal transducer and 
activator of transcription (STAT) 1 (Schroder et al., 2004).  Similarly, IFN-γR2 is able to recruit 
a JAK2 kinase which then undergoes autophosphorylation allowing it to activate the JAK1 
kinase on IFN-γR1 via transphosphorylation.  This kinase, JAK1, then phosphorylates tyrosine 
residues on IFN-γR1 leading to the recruitment, and subsequent phosphorylation, of STAT1. 
This phosphorylated STAT1 is now active and can translocate to the nucleus. 
The genes that are regulated by IFN-γ vary significantly (Schroderet al., 2004).  This 
cytokine is capable of influencing the transcription of genes involved in the antigen presentation 
pathway, antiviral response, and is both anti-proliferative and apoptotic.  In the presence of IFN-
γ chemoattractants for T cells, monocytes and macrophages are produced, nitrous oxide is 
produced to dilate blood vessels and there is an increase in adhesion molecules on endothelial 
cells and leukocytes. These responses increase the extraversion of leukocytes at the site of the 
inflammatory response leading to phagocytosis of any foreign objects, antibody production and 
cytokine release. 
1.6.3.3 Interleukin-10   
Unlike TNF-α and IFN-γ, interleukin-10 (IL-10) functions to limit the inflammatory 
response. Multiple immune cell types are capable of producing IL-10; however the primary 
source is macrophages (Ruffell et al., 2014, Sonderegger et al., 2012).  Interestingly, 
macrophages are also the cell population most influenced by IL-10 suggesting at least some auto-
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regulation (Moore et al., 2001).  Structurally IL-10 is similar to IFN-γ as it is a homodimer 
(Zdanov et al., 1995).  The biological activities of IL-10 include down regulation of major 
histocompatibility complex class II proteins on macrophages (Bogdan et al., 1991) as well as 
inhibition of TNF-α (de Waal Malefyt et al., 1991) and IFN-γ (Ito et al., 1999) production.  
These activities of IL-10 allow the host immune response to be modulated in order to prevent 
unnecessary damage to the healthy tissue at the site of inflammation. 
As the structure of IL-10 is similar to that of IFN-γ, it is no surprise that their respective 
receptors also share structural similarity. Like IFN-γ, the IL-10 receptor complex is comprised of 
two chains, IL-10R1 and IL-10R2 (Kotenko et al., 1997).  Unlike IFN-γ, the IL-10 receptor is 
lacking a soluble form as it has only been detected as a membrane associated receptor in vivo 
(Mooreet al., 2001).  A study performed in a JAK1 knockout mouse model demonstrated that 
macrophages lacking JAK1 do not respond to the presence of IL-10 (Rodig et al., 1998). Further 
studies in mutant mouse macrophage cells found that STAT3, a transcription factor, was also 
required in order to induce macrophage proliferation through IL-10 stimulation (O'Farrell et al., 
1998).  This situation is similar to that of the JAK/STAT pathway previously discussed and the 
proposed method of IL-10 signaling closely mimics that of IFN-γ (Kotenkoet al., 1997).  It is 
through the binding of IL-10 to either IL-10R1, which then recruits IL-10R2, or the complete IL-
10R complex, that the autophosphorylation of the tyrosine kinases and transphosphorylation of 
JAK1 can occur.  This phosphorylation of JAK1 then recruits STAT3 which, after undergoing its 
own phosphorylation by JAK1, is able to translocate to the nucleus and begin altering the 
transcription activity of the cell.  
As with most cytokines the biological activities of IL-10 varies depending on the 
properties of the cell upon which it is acting.  In the case of cells such as macrophages, IL-10 is 
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responsible for the inhibition of IL-1, TNF-α as well as numerous other cytokines and colony 
stimulating factors, which are glycoproteins capable of inducing differentiation and proliferation 
of hematopoietic stem cells (Mooreet al., 2001).  This inhibition of IL-1 and TNF-α is key to the 
anti-inflammatory properties of Il-10.  The prevention of nitric oxide synthesis, and thereby the 
reduction in vasodilation, is another property of IL-10; however, rather than being a direct action 
upon nitric oxide synthases, it is the down regulation of the upstream signalling messengers 
TNF-α and IFN-γ that is responsible for the reduction in nitric oxide synthesis (Flesch et al., 
1994).   
1.6.3.4 Nuclear factor κβ 
Essential in T-cell and B-cell differentiation, as well as having anti-apoptotic and pro-
inflammatory effects, the transcription factor NFκβ plays a vital role in the inflammatory 
response (Baeuerle and Henkel, 1994). There are five different members of the NFκβ family of 
proteins, RelA (p65), c-Rel, RelB, NFκβ1 (p50) and NFκβ2 (p52) (Liou, 2002). NFκβ1 and 
NFκβ2 contain a c-terminal domain that must be removed by proteolytic processing to become 
active. 
As a potent transcription factor, the activation of NFκβ is tightly regulated through 
another family of proteins called inhibitors of NFκβ, or IκB (Auphan et al., 1995).  The common 
sequence between the IκB family and NFκβ1/NFκβ2 is known as an ankyrin repeat.  Typically, 
NFκβ exists in the cytoplasm as a p50/p65 heterodimer which is bound by IκB. In order for 
NFκβ to perform its action as a transcription factor, the IκB must be degraded.  This degradation 
is accomplished through the activity of the IκB kinase complex (Baeuerle and Baltimore, 1996).  
This complex phosphorylates the appropriate region of the inhibitor leading to its 
polyubiquitination and degradation.  Activation of NFκB is only one part of the immune 
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signaling cascade and cytokines such as TNF- α, IFN-γ and IL-10 have demonstrated the 
capability to alter the activation of this essential transcription factor. 
The activation of NFκβ via TNF-α requires the destruction of any bound IκB and the 
mechanism may be different depending upon whether TNF-R1 or TNF-R2 is considered 
(Bradley, 2008, Devin et al., 2000).  In the case of TNF-R1 two components are required for 
activation of the IκB kinase complex, TRAF2 and the death domain kinase receptor-interacting 
protein (RIP) (Devinet al., 2000).  Initially TRAF2 brings the IκB kinase complex to TNF-R1 
and RIP activates the kinase complex leading to the degradation of the inhibitor and thereby the 
activation of NFκβ.  Although the activation of NFκβ through TNF-R2 is not as well 
characterized, it appears to also occur through an interaction with TRAF2 (Bradley, 2008).  
Should this be the case, the remaining signalling cascade would be similar to that of TNF-R1. 
 In addition to its capacity to signal through STAT3, IFN-γ is also capable of inducing 
expression of NFκβ, albeit not by itself (Cheshire and Baldwin, 1997, Rimbach et al., 2000). A 
study investigating the interaction between macrophages and human endothelial cells determined 
that when macrophages were exposed to IFN-γ they, in turn, increased NFκβ activation and 
DNA binding (Rimbachet al., 2000).  Although this is not a direct effect of IFN-γ, it 
demonstrates that this cytokine is capable of inducing the activation of NFκβ.  It appears that 
IFN-γ must act indirectly, as in the case of macrophage assisted endothelial NFκβ production, or 
in combination with other cytokines such as TNF- α in order to elicit activation of NFκβ 
(Cheshire and Baldwin, 1997).  When endothelial cells or pre-neuronal cells were co-stimulated 
with IFN-γ and TNF- α, activation of NFκβ occurred even at concentrations where the individual 
cytokines would have had no effect.  This indicated a synergistic effect between these cytokines 
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for the activation of this transcription factor and it was determined that in endothelial cells this 
synergism occurred due to increased degradation of IκB.   
 Anti-inflammatory cytokines, such as IL-10, are capable of repressing activation of 
NFκB (Wang et al., 1995). This study, conducted in human monocytes, found that IL-10 was 
able to inhibit NFκB in a dose dependent manner.  Further investigation of IL-10 and its impact 
on NFκB activation revealed that IL-10 is capable of preventing activation of the IκB kinase 
complex and directly inhibits DNA binding of activated NFκB (Schottelius et al., 1999). This 
inhibition of NFκB would prevent transcription of many pro-inflammatory cytokines and 
chemokines making IL-10 a powerful anti-inflammatory signal.  
1.7 Surgical methods 
1.7.1 Gut Loop Model 
The ligated loop model, or gut loop model, has been used in pigs to investigate amino 
acid metabolism of specific regions of the small intestine (Adegoke et al., 1999a, Adegoke et al., 
1999b).  This model has also been used to demonstrate PepT1-mediated transport of substrates 
including glycyl-sarcosine (Pan et al., 2002, Hindlet et al., 2007) as well as pharmaceutical 
compounds (Yang and Smith, 2013, Chu et al., 2001) and bacterial peptides (Wu and Smith, 
2013, Buyse et al., 2002).  Differences among the studies described in the literature include both 
intestinal positioning and length of the loops, but the methodology was similar in all studies.  In 
all cases, the intestine was exposed and the gut segment to be perfused was isolated and 
cannulated to create a closed system.  The mesentery was undisturbed, allowing for an in vivo 
assessment of intestinal activity.  The advantages of this model for investigating intestinal 
substrate transport include the ability to isolate and compare specific intestinal segments ( i.e. 
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jejunum versus ileum).  Furthermore, it allows for careful control of the composition of luminal 
contents presented to the intestinal mucosa.  Finally, it permits the implantation of multiple loops 
in one animal thereby reducing inter-animal variability.  The ligated loop model had been used 
previously (Nichols and Bertolo, 2008), and is ideal for investigations of the ontogeny of peptide 
transport in the Yucatan piglet and to study the impact of fMLP on markers of inflammation in 
healthy and atrophied intestine. 
1.7.2 Intestinal Resection 
Animal models have contributed important information about the adaptive capacity of the 
small intestine in response to resection, but most of the data were derived from mature rodent 
models which may not be of relevance to neonates.  Morphological and biochemical changes 
have been described post-resection in rat models treated with enteral feeding (Vanderhoof et al., 
1992, Cronk et al., 2000).  Fewer studies have been conducted in a clinically relevant piglet 
model, but include both enteral (Heemskerk et al., 1999) and parenteral  feeding strategies 
(Bartholome et al., 2004).  A Yucatan miniature piglet model of intestinal adaptation with an 
80% jejuno-ileal resection was characterized by my supervisors research group (Dodge et al., 
2012).  The study employed a combined protocol of enteral and parenteral feeding, and 
demonstrated profound early adaptive capacity in the distal ileum in piglets, compared to 
parenteral- or sham-treated controls.  Piglets had greater intestinal length with greater cellular 
proliferation index and ornithine decarboxylase activity in the distal ileum after receiving enteral 
feeding.  In that study, the enteral diet was elemental, containing free amino acids.  The evidence 
that PepT1 is maintained with intestinal injury (Satoh et al., 2003) and that transporter regulation 
is partially substrate driven (Walker et al., 1998) makes it a worthy target to investigate whether 
dipeptides might provide a nutritional advantage over free amino acids to support nitrogen 
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uptake.  Our piglet model is well-suited to investigate the potential effects of enterally provided 
dipeptides on intestinal adaption in neonates. 
 1.8 Problem of Investigation  
 
1.8.1 Background 
Differences in the location and concentration of PepT1 mRNA along the small intestine 
during development have been reported in rats (Shen et al., 2001), chickens (Chen et al., 2005, 
Gilbert et al., 2007a) and pigs (Wang et al., 2009).  In Tibetan piglets, PepT1 mRNA increased 
in the duodenum and jejunum from birth to the middle of the suckling period, after which the 
expression decreased in these intestinal regions.  This suggests that PepT1 and peptide transport 
are potentially important in the early life of the suckling neonate.  Characterizing the ontogeny of 
PepT1 in the neonate is necessary for the development of effective feeding strategies for both 
healthy and sick infants.  Dipeptide transport capacity via PepT1 across the length of the 
developing intestine has not been previously reported in our piglet model.   
Short bowel syndrome induced through intestinal resection reduces  absorptive capacity 
(Sukhotnik et al., 2002) resulting in nutrient deficits and prolonged medical care.  A piglet model 
of short bowel syndrome was characterized which demonstrated greater adaptive response in 
animals receiving enteral nutrition (Dodge et al., 2012).  PepT1 expression is maintained during 
intestinal stress while certain free amino acid transporters are reduced in number (Satoh et al., 
2003) and expression is at least partially substrate driven (Ferraris et al., 1988).  With PepT1 
expression maintained during intestinal injury and the increased adaptive response of the 
intestine in enterally fed piglets, I investigated the adaptive benefits of enterally provided 
dipeptides in our piglet model of short bowel syndrome. 
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Escherichia coli produces many chemotactic compounds, but the major neutrophil 
chemotactic substance produced is formyl-methionyl-leucyl-phenylalanine (fMLP) (Marasco et 
al., 1984).  Transport of fMLP by PepT1 has been demonstrated in cell culture (Merlin et al., 
1998) and in rats using intestinal perfusion (Buyse et al., 2002).  Intestinal perfusion in rat 
jejunum induced invasion of neutrophils into the mucosa and altered villus morphology, signs of 
intestinal inflammation.  Transport of fMLP has been implicated in exacerbating inflammatory 
bowel disease, with increased transport being correlated with increased expression of PepT1. 
Although it has been demonstrated that presence of dipeptides can prevent transport of fMLP via 
PepT1, the question of whether parenteral nutrition and associated gut atrophy increases the 
susceptibility to bacterially induced inflammation has yet to be addressed.  
1.8.2 Questions to be addressed 
 
Although the importance of peptide transport has been noted in a wide range of 
organisms, little information is available on peptide absorption in the piglet.  The piglet is a key 
model organism for neonatal development in humans, and swine are vital to the agricultural 
industry in Canada.  As such, information on peptide uptake in piglets has important applications 
in human health and swine production.  The research programme outlined in this thesis was 
performed in order to further elucidate peptide transport in Yucatan miniature pigs and to 
delineate potential benefits of enteral dipeptides.   
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1.8.3 Specific Objectives 
 
1) Identify the potential for peptide transport in the piglet small intestine and determine 
if there were any differences in peptide transport due to developmental changes or 
dietary alterations (Chapter 2) 
2) Study the potential ameliorative effects of enterally-delivered dipeptides in a 
surgically shortened intestine using a piglet model of short-bowel syndrome (SBS) 
(Chapter 3). 
3) Investigate the impact of a bacterial peptide, formyl-methionyl-leucyl-phenylalanine 
(fMLP) on intestinal inflammation in a model of gut atrophy (Chapter 4). 
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Chapter 2: Ontogeny of dipeptide uptake and peptide 
transporter 1 (PepT1) expression along the 
gastrointestinal tract in the neonatal Yucatan 
miniature pig 
 
 
The work presented in this chapter was funded in part by a grant from the Natural 
Sciences and Engineering Research Council of Canada.  It represents work that was presented at 
Experimental Biology 2008 in San Diego, CA, U.S.A and was published in the British Journal of 
Nutrition in 2013 (M.G. Nosworthy, R.F.P Bertolo and J.A. Brunton. Ontogeny of dipeptide 
uptake and PepT1 expression along the gastrointestinal tract in the neonatal Yucatan miniature 
pig.  Br J Nutr. 2013 12:1-7). JAB and RFP were responsible for designing the study, MGN 
carried out the animal work in addition to the laboratory and statistical analyses.  
A significant proportion of dietary amino acids are absorbed as small peptides through 
the activity of the intestinal di/tripeptide transporter PepT1.  The characterization of PepT1 in the 
developing neonate is of tremendous importance for the advancement of effective feeding 
strategies for both healthy and sick infants.  In this study, we determined PepT1 transport 
capabilities and relative quantities of PepT1 mRNA at specific locations along the 
gastrointestinal tract of piglets during suckling and post-weaning.  
Hypothesis: All intestinal regions studied will demonstrate the capacity to transport dipeptides. 
Additionally, the intestinal capacity for peptide uptake will change during development.   
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2.1 Abstract  
 
The H
+
-coupled transporter, PepT1 is responsible for the uptake of dietary di- and tri-peptides in 
the intestine.  Using an in vivo continuously perfused gut loop model in Yucatan miniature pigs, 
we measured dipeptide disappearance from four 10 cm segments placed at equidistant sites along 
the length of the small intestine.  Pigs were studied at 1, 2, 3 (suckling) and 6 weeks (post-
weaning) post-natal age. Transport capability across the PepT1 transporter was assessed by 
measuring the disappearance of 
3
H-glycyl-sarcosine; real time RT-PCR was also used to quantify 
PepT1 mRNA.  Each of the regions of intestine studied demonstrated the capacity for dipeptide 
transport.  There were no differences among age groups in transport rates measured in the most 
proximal intestine segment.  Transport of 
3
H-glycyl-sarcosine was significantly higher in the 
ileal section in the youngest age group (1 week) compared to the other suckling groups; however,  
all suckling piglet groups demonstrated lower ileal transport compared to the post-weaned pigs.  
Colonic PepT1 mRNA was maximal in the earliest weeks of development and decreased to its 
lowest point by week 6. These results suggest that peptide transport in the small intestine may be 
of importance during the first week of suckling and again with diet transition following weaning.      
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2.2 Introduction  
 
Dietary protein is absorbed from the intestinal lumen as its constituent amino acids as well as 
small peptides containing two or three residues.  The protein responsible for dietary di- and tri- 
peptide transport is PepT1, a member of the proton-coupled oligopeptide transporter (POT) super 
family of proteins (Daniel, 2004).  PepT1 is localized to the apical membrane of intestinal villi, 
allowing it access to the digesta passing through the lumen.  Studies that have investigated 
PepT1 mRNA at distinct regions along the intestine have reported variable results (Chen et al., 
1999, Li et al., 2008, Wang et al., 2009), likely due to different animal models.  In rats and mice, 
the amount of PepT1 mRNA does not change across the length of the small intestine (Lu and 
Klaassen, 2006, Rome et al., 2002, Erickson et al., 1995); however in the developing chick 
intestine, the highest quantities were found in the duodenum and jejunum (Li et al., 2008). In 
adult humans and rats, higher concentrations of PepT1 mRNA in the duodenum and jejunum 
have also been reported (Terada et al., 2005, Herrera-Ruiz et al., 2001).  In contrast, Chen et al. 
reported similar expression of PepT1 mRNA across the entire length of the small intestine of 
mature sheep, dairy cows, pigs and chickens (Chen et al., 1999). 
  Few studies have reported developmental changes in PepT1.  Differences in the location 
and concentration of PepT1 mRNA along the small intestine with increasing age have been 
reported in rats (Shen et al., 2001) and chickens (Chen et al., 2005, Gilbert et al., 2007a). PepT1 
protein increased linearly with age in chickens, but there was a decrease in PepT1 mRNA in rats 
between postnatal days 4 and 50.  Shen et al. demonstrated that even though PepT1 mRNA 
expression was at its highest point 3-5 days after birth in a neonatal rat model, it declined rapidly 
at all locations in the small intestine during the following days of suckling, suggesting that 
PepT1 and peptide transport are potentially important in the early life of the suckling neonate 
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(Shen et al., 2001).  In piglets, D’Inca et al. determined that there was a dramatic decrease in 
PepT1 mRNA expression within the first 48 hours after birth; however, intrauterine growth 
restriction delayed this adaptation, further supporting the importance of peptide transport in the 
newborn (D'Inca et al., 2011). 
In adult humans, a significant proportion of amino acids are absorbed as di- and 
tripeptides, and dipeptides are absorbed faster than free amino acids in the jejunum due to the 
high capacity for uptake by PepT1 (Ganapathy V, 1994).  A high turnover rate and expression 
level of PepT1 contributes to the rapid uptake of peptides (Steinhardt and Adibi, 1986).  The 
efficiency in uptake of small peptides combined with the lower osmolarity of peptide solutions 
support the use of peptides rather than free amino acids in therapeutic enteral formulas (Boza et 
al., 2000).  In neonates, proteolytic capacity is not as well developed as in adults, due to 
significantly lower production of pepsin (Henderson et al., 2001). Compared to adults, a higher 
proportion of amino acids would be present in the neonatal gut as small peptides.  As such, the 
capacity for peptide transport may be high to support optimal nutritional status and growth.  
Indeed, alanyl-glutamine is currently being studied as a potential dietary supplement, and has 
been reported to increase the nutritive status and intestinal barrier function in human neonates 
(Lima et al., 2007) as well as to aid in the maintenance of cellular glutathione concentrations 
during oxidative stress (Alteheld et al., 2005). Although the absorption of small peptides is 
important in the healthy individual, the bioavailability of peptides in times of intestinal duress 
may be of particular importance.  In addition, the added benefits of stability, hypotonicity and 
palatability (Silk et al., 1982) support the importance and usefulness of dipeptide preparations for 
modern clinical treatments.  
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Characterizing the ontogeny of PepT1 in the neonate is of tremendous importance for the 
development of effective feeding strategies for both healthy and sick infants.  The piglet is an 
excellent model for the human neonate, and especially preterm infants (Shulman, 1993). 
Neonatal pigs share similar patterns of intestinal development with humans, as well as similar 
nutritional requirements. Dipeptide transport capacity via PepT1 and the effects of development 
have not been previously reported in this model.  In this study, we determined PepT1 transport 
capabilities and relative quantities of PepT1 mRNA at specific locations along the 
gastrointestinal tract of piglets during suckling and post-weaning.  
2.3 Experimental Methods 
 
2.3.1 In situ perfusion (gut loop model)  
 
Sixteen Yucatan miniature piglets (N = 4 per group) were obtained from the breeding 
herd at Memorial University of Newfoundland (average birthweight 1.01 ± 0.03 kg; average 
growth rate from birth to 1 month of age: 45 ± 3 g/kg bodyweight/d).  All procedures were 
approved by the Institutional Animal Care Committee, and were in accordance with the 
guidelines of the Canadian Council on Animal Care. Piglets were studied at 1, 2, 3 or 6 weeks of 
age. Piglets in this herd are weaned at 4 weeks old to a standard pelleted grower pig diet based 
on wheat, barley, oats and canola meal (15.6% crude protein, 3.75% crude fat, 12.1 MJ/kg 
digestible energy) (Eastern Farmers Co-op, St. John’s, NL); preweaning piglets were exclusively 
suckled by sows fed a typical lactation diet with 14% crude protein and 3% crude fat.  To avoid 
fasting (which may alter PepT1 expression or function (Ma et al., 2012)), the in situ study was 
initiated within 2 h of separating the piglets from the sows at 1, 2 or 3 weeks of age and within 2 
h of last feed for 6 week old piglets. Anaesthesia was induced with an intramuscular injection of 
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22 mg/kg ketamine hydrochloride (Bimeda-MTC, Cambridge, ON) plus 0.5 mg/kg 
acepromazine (Vétoquinol Canada Inc., Lavaltrie, QC).  General anaesthesia was maintained 
with 1-2% isoflurane (Abbot Laboratories Ltd., Montreal, QC) delivered with 1.5 L/min oxygen.  
Body temperature was maintained via a homeothermic blanket system that automatically 
adjusted heat output in response to a rectal temperature probe (Harvard Apparatus, Saint-
Laurent, QC).  A mid-line incision was made in the abdomen to open the peritoneum.  The 
complete length of the small intestine (SI) was measured and four equidistant regions were 
marked for loop placement. The most proximal jejunal loop (0%) was defined as 15 cm from the 
ligament of Treitz.  Closed loops of intestine consisted of 10-cm sections of intestine with inlet 
and outlet cannulas (ID, 1/16 in.; OD, 1/8 in., Watson Marlow, Cornwall, UK) inserted through a 
small perforation at both ends of the 10 cm.  In total, four loops were placed at 0, 25, 50 and 75% 
of SI length.  Each isolated gut loop was perfused with a dipeptide-containing buffer that was re-
circulated through the loop for the duration of the study by a multi-channel peristaltic pump 
(Watson Marlow, Cornwall, UK).  The perfusate (65 ml) contained 5 mM glycyl-sarcosine (gly-
sar) with 37 kBq 
3
H-glycyl-sarcosine (Moravek, Brea, CA) in PBS (144.6 mM NaCl, 15.9 mM 
Na2HPO4, 1.2 mM NaH2PO4), pH 6.0, and was maintained at 37°C for the duration of the study.  
Perfusions through each closed loop continued for 120 min.  A 1 mL sample of perfusate from 
each closed loop was removed every 10 min, to determine isotope disappearance.  During the 
procedure the exposed intestines were kept moist with warmed saline and covered with gauze 
and plastic wrap.  Heart rate and blood oxygenation were monitored via pulse-oximetry 
(Surgivet, Dublin, OH) throughout the experiment.  At the end of the perfusion period the loops 
were excised by cautery, flushed with cold 0.9% saline, placed on ice, cut longitudinally and 
scraped with a microscope slide to remove the mucosa. Samples were also removed from the 
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apex of the spiral colon and flushed, and all tissues were immediately flash frozen in liquid 
nitrogen and stored at -80°C until further analyses. 
2.3.2 Disappearance of 
3
H-glycylsarcosine 
 
Sampled perfusate (100 µL) was added to 4 mL Scintiverse (Fisher Scientific, Ottawa, ON) for 
liquid scintillation counting.  The specific radioactivity (SRA) was calculated as the mean 
disintegrations per minute (dpm) per µmol of glycyl-sarcosine present in the perfusate. SRA was 
calculated at baseline (prior to perfusion) and in each of the perfusate samples taken over the 
course of the 2-h study.  The SRA was then used to determine the total quantity of glycyl-
sarcosine.  Rate of disappearance of glycyl-sarcosine was determined via area under the curve 
using GraphPad Prism 4.0. Perfusates were also derivatized with phenylisothiocyanate and 
analyzed using HPLC (Bidlingmeyer et al., 1984).  Complete fraction collection was used to 
determine whether the isotope was associated with glycyl-sarcosine, glycine or some other 
metabolite.  
2.3.3 Real-time RT-PCR 
 
PepT1 mRNA was measured in mucosa sampled from each of the perfused intestinal loops.  
Samples of colon were also analyzed.  RNA was extracted using the Qiagen RNEasy Mini kit 
(Qiagen Inc., Mississauga, ON) according to the manufacturer’s protocol.  Relative 
concentration and purity were determined by measuring the absorbance at 260 and 280 nm using 
a NanoDrop 1000 (NanoDrop Technologies, Wilmington, DE).  RNA integrity was visualized 
via the agarose gel visualization of the 28S:18S ratio.  cDNA was created according to the 
protocol outlined in the QuantiTect (Qiagen Inc., Mississauga, ON) reverse transcriptase manual. 
1 µg of total RNA was used in the reverse transcription reaction.  Taqman probes were utilized 
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in the PCR reaction. The sequences of the primers and probes were as follows: PepT1 forward 
primer  5’ d CTGGAGTTCTCCTATTCTCA 3’,  reverse primer 5’ d 
AACAGCCACGGTCAACAG 3’, probe sequence for PepT1 5’ d BHQ-2-
TCCTTCCAACATGAAGTCGGTGC-Pulsar 650 3’.  β-actin was used as an internal control 
with the following sequences: forward primer 5’ d CCCAGCACGATGAAGA 3’, reverse primer 
5’ d CGATCCACACGGAGTC 3’,  probe 5’ d FAM-TCAAGATCATCGCGCCTCCAGA-
BHQ-1 3’.  The accession numbers for the template sequences were AY180903.1 for PepT1(23) 
and AY55069 for beta-actin.  The Lightcycler (Roche, Indianapolis, IN) was set to the following 
conditions: 15 min at 95°C, 40 cycles of 1 min at 95°C and 1 min at 55°C, and a 40°C incubation 
for 1 min.  Reaction efficiency for PepT1 was 0.94 ± 0.03 and β-actin reaction efficiency was 
0.96 ± 0.06. Each sample was run in triplicate and analyzed using the Livak method (2
-
ddCt
)(Livak and Schmittgen, 2001).   
2.3.4 Statistical analyses 
 
Data were analyzed by one-way (colonic PepT1 mRNA) or two-way repeated measures ANOVA 
(overall uptake of glycyl-sarcosine) with Bonferroni’s protected means separation test. The 
variables analyzed in the two-way ANOVA were age, intestinal location and their interaction. 
Uptake data over time were tested for linearity using least squares regression. Sample size was N 
= 4 piglets per age group and differences were noted as significant if p < 0.05 (GraphPad Prism 
4.0, La Jolla, CA). 
2.4 Results  
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Throughout the perfusion studies, all piglets remained stable, well oxygenated and maintained a 
core body temperature above 37.5˚C. 
2.4.1 Dipeptide disappearance 
 
The proportion of 
3
H associated with glycyl-sarcosine accounted for greater than 90% of the 
radioactivity in the perfusates at baseline, determined through HPLC fraction collection, while 
glycine contained less than 5% of the label.  This suggests that the dipeptide did not degrade 
intraluminally and was available for transport. Glycyl-sarcosine transport occurred linearly in all 
intestinal loops in all animals studied, except in the most distal loop (75%) in week 1 and 3 
piglets, and in the 0% loop in piglets at week 6 (Fig.2.1). In order to assess how dipeptide uptake 
might change along the longitudinal axis of the small intestine as the animal ages, we compared 
glycyl-sarcosine uptake between age groups at the four sites of the small intestine (Fig. 2.2).  
Overall, there was a significant effect of age (p < 0.0001), intestinal location (p < 0.005) and age-
by-location interaction (p < 0.0005).  When compared by intestinal location, dipeptide uptake 
was remarkably consistent at the most proximal site (0%) across all age groups.  At the mid-
jejunum site (25%), glycyl-sarcosine uptake in 1 week old pigs was twice that in pigs 2 and 3 
weeks old (p < 0.05), with 6 week old pigs intermediate.  In the distal jejunum (50%), greater 
uptake occurred in the post-weaning animals (6 weeks) compared to the week 2 animals (p < 
0.05), with uptake in piglets at 1or 3 weeks of age intermediate.  The uptake of glycyl-sarcosine 
in the ileum (75%) for week 6 animals was about twice that for piglets aged 2 and 3 weeks (p < 
0.001), and 30% greater than piglets at 1 week (p < 0.05).  Within age groups, 1 week old 
animals had greatest uptake in mid-jejunum and ileum (p < 0.05).  In 6 week old animals, there 
was a notable gradient of glycyl-sarcosine uptake with the lowest uptake in the proximal jejunum 
up to a 3-fold higher uptake in the ileum (Fig. 2.2). 
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Fig. 2.1 Total glycylsarcosine disappeared from closed loops of small intestine during the 2 h 
perfusion study. Position of each intestinal loop is indicated by its relative position from the 
ligament of Treitz: (a) 0, (b) 25, (c) 50 and (d) 75 %. Values are means with their standard errors 
(N=4 for each group).  
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Fig. 2.2 Rate of glycyl-sarcosine (Gly-Sar) uptake from closed loops of small intestine.  
Intestinal position is given as distance from the ligament of Treitz as a percent of the total length 
of the intestine.  Uptake was determined by measuring the disappearance of 
3
H-glycyl-sarcosine.  
Data are expressed as mean ± SD (N = 4 for each bar) and were analyzed by two-way ANOVA. 
Significant effects of age (p < 0.0001), intestinal location (p < 0.005) and age-by-location 
interaction (p < 0.0005) were observed.  Lines represent significant differences between 
intestinal sections within an age group (*p < 0.05, **p < 0.01). Differing letters represent 
significant differences (p < 0.05) within each specific intestinal site, compared among age 
groups.   
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2.4.2 Quantification of PepT1 mRNA in the intestine 
 
The PCR results from the small intestinal tissue samples were highly variable, thus no significant 
differences in PepT1 mRNA were detected (Fig. 2.3).  PepT1 mRNA was detected in the colon 
of all animals (Fig. 2.4); however, the quantity was ~10% of that measured in the proximal 
jejunum of piglets at 1 week of age, and ~2% of that found in the proximal jejunum of post-
weaning animals (p < 0.05).  Although present in similar abundance at ages 1, 2 and 3 weeks, 
colonic PepT1 mRNA in post-weaned pigs was only 10% of that seen than in suckling pigs (p < 
0.05) (Fig. 2.4).  
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 Fig. 2.3 Real time RT-PCR analysis of PepT1 mRNA closed loops of small intestine.  Intestinal 
position is given as distance from the ligament of Treitz as a percent of the total length of the 
intestine.  Week 1 samples were set at 1 for comparison purposes (Livak and Schmittgen 2001).  
Data are expressed as mean ± SD (N = 4 for each bar). 
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Fig. 2.4 Real time RT-PCR analysis of PepT1 mRNA in the colon at four ages.  Week 1 samples 
were set at 1 for comparison purposes (Livak and Schmittgen 2001).  Data are expressed as mean 
± SD (N = 4 for each bar) and were analyzed by one-way ANOVA. Bars with differing letters 
are significantly different, p < 0.05. 
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2.5 Discussion  
 
Although the porcine peptide transporter has been cloned and characterized (Klang et al., 2005), 
there has been little investigation into the ontogeny of porcine PepT1.  The objective of this 
study was to evaluate the ontogenic pattern in peptide transport capability and PepT1 mRNA 
quantity in the small intestine of the Yucatan miniature pig as it develops from suckling to a 
post-weaned state.  Clinically, such information is necessary to appropriately design feeding 
regimens for infants.  This objective was accomplished through the use of a hydrolysis resistant 
dipeptide tracer, 
3
H-glycyl-sarcosine, and real time RT-PCR for mRNA analysis.  From these 
techniques it was determined that there was little variation in uptake of glycyl-sarcosine at any 
location in the small intestine during the suckling period; however in the post-weaning period, 
there was a distinct gradient in rate of uptake which was greatest in the distal small intestine.  
Small intestinal PepT1 mRNA was extremely variable at all locations measured in the small 
intestine at each age, whereas colonic PepT1 abundance declined dramatically after the animals 
were weaned. 
In this study, small intestinal loops were perfused with a dipeptide-containing solution 
and uptake was calculated from the disappearance of 
3
H-glycyl-sarcosine.  This in situ model is 
ideal to isolate specific regions of the intestine for study by allowing multiple loops per animal, 
limiting systemic effects of the perfusate and still maintaining first-pass metabolism (Nichols and 
Bertolo, 2008, Adegoke et al., 1999a, Adegoke et al., 1999b).  For these reasons, this model was 
selected to examine dipeptide uptake in the piglet model.   
Absorption of glycyl-sarcosine and PepT1 mRNA was detected in the loops at all four 
locations in the small intestine.  There was a significant effect of intestinal location on the uptake 
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of the dipeptide glycyl-sarcosine, particularly in post-weaning pigs (Fig. 2.2).  Uptake of glycyl-
sarcosine was relatively consistent in all intestinal locations examined in the older suckling 
animals (weeks 2 and 3).  So once an animal was no longer suckling and was weaned onto a 
solid grain-based diet, there was a greater capacity for dipeptide transport in the ileum.  
Components of sow milk are readily digested and absorbed in the proximal parts of the small 
intestine (Mavromichalis et al., 2001, Buddington et al., 2001), so it is likely that the dietary 
stimulus for PepT1 upregulation in more distal portions of the ileum may not be present in 
luminal contents.  In contrast, products of protein hydrolysis in grain-based diets with lower 
digestibility consumed by weaned animals would likely reach the ileum before absorption (Low, 
1979), providing a substrate for PepT1, and perhaps a stimulus for PepT1 upregulation in the 
distal intestine of the post-weaned piglet. In this respect, the distal ileum may be important for 
optimal nitrogen absorption in the period immediately following a diet transition.  Alternatively, 
the transition to solid feeding can be considered a period of intestinal injury and inflammation 
for the milk-fed piglet (Moeser et al., 2007, Pie et al., 2004) and such injury could lead to a 
stimulation of peptide uptake capacity (Vavricka et al., 2006).  With respect to age, dipeptide 
uptake tended to follow a U-shaped curve with higher uptake in 1 week old and post-weaned 
piglets.   
Although PepT1 is present in the small intestine, we have also identified its presence in 
the colon of the developing piglet.  Our results demonstrated that PepT1 mRNA is present in 
colonic tissues until after weaning occurs (week 6).  This may be an adaptive response that 
occurs post-weaning; as the distal small intestine increases its capacity for oligopeptide 
absorption, the colon reduces the transcription of PepT1 mRNA.  Shen et al. reported that PepT1 
presence in the colon was transient, because by day seven no PepT1 mRNA was found in the 
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colon of developing rats (Shen et al., 2001).  PepT1 has been found in the colon of rats at later 
time points (Shi et al., 2006b), but its presence has been primarily related to a state of intestinal 
injury such as gut resection.  PepT1 has also been detected in the colon of humans that have 
undergone intestinal resection (Ziegler et al., 2002).  PepT1 is present in the colon of humans 
with inflammatory bowel disease (Merlin et al., 2001) and it has been shown that PepT1 is 
capable of transporting fMLP, which is a bacterial peptide.  As such, PepT1 may be responsible 
for the exacerbation of inflammatory bowel disease.  Colonic PepT1 mRNA and protein were 
also higher in patients with massive bowel resections, when compared to control subjects 
(Ziegler et al., 2002).  A study in rats demonstrated an increase in PepT1 protein in the colon of 
animals with intestinal resection that were fed chow (Shi et al., 2006b), whereas rats fed an 
elemental diet did not express any PepT1 mRNA in colonic tissues (Lardy et al., 2006).  
Findings such as these underscore the importance of peptide presence in the lumen of the colon 
for the induction of PepT1.  Although colonic peptide transport is extremely low when compared 
to the whole small intestine, in the event of intestinal injury or malnutrition, capacity for 
oligopeptide uptake may be increased through the up-regulation of PepT1, thereby recovering  
nutritionally valuable substrates.  Whether this also leads to greater uptake of pathogenic 
bacterial peptides remains to be determined.   
To understand the potential impact of peptide transport, it is important to consider the 
variable affinity of PepT1 substrates.  Alanyl-alanine, for example, is a high affinity substrate for 
PepT1 (Ki of 0.08 ± 0.01 mM) whereas glycyl-sarcosine is classified as a medium affinity 
substrate with a Ki of 1.1 ± 0.1 mM, determined in Caco-2 cells (Brandsch et al., 1998, Brandsch 
et al., 1999).  Previous work on glycyl-sarcosine transport in porcine jejunum, using an Ussing 
chamber system, demonstrated dipeptide uptake of approximately 600 nmol/cm
2
/2 h (modified 
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from Winckler et al) (Winckler et al., 1999).  In our study, using the more physiological ligated 
loop model, we found that the overall average glycyl-sarcosine uptake was 424 ± 226 
nmol/cm
2
/2 h.  Thus, the data from our in situ model are comparable to previous in vitro findings 
with the same non-nutritional dipeptide and likely underestimate the transport rates of dietary 
dipeptides with higher PepT1 transporter affinity.   
There are two possible mechanisms for the intestinal transport of oligopeptides: PepT1- 
mediated transcellular transport (Daniel, 2004) and paracellular transport (McCollum and Webb, 
1998). The role of these pathways in intestinal oligopeptide transport is not yet fully understood, 
and there is increasing evidence that the paracellular pathway may be of some importance in 
absorption of small peptides and peptidomimetic drugs (Lafforgue et al., 2008, Menon and Barr, 
2003).  It has been well documented that the small intestine of suckling animals demonstrates 
greater paracellular transport at younger ages (Udall et al., 1981, Weaver et al., 1984). Thus, it is 
possible that paracellular transport could mask low PepT1 activity during suckling. We also 
observed the greatest disappearance of glycyl-sarcosine in the ileum of the post-weaning 
animals.  Overall, if paracellular transport had significant impact on the transport of glycyl-
sarcosine in our piglets, it would have been most prominent at the younger ages (weeks 1, 2 and 
3) rather than the post-weaning state.   
In summary, we have examined the ontogenic changes of the peptide transporter PepT1 
in a piglet model of the developing intestine.  These results have demonstrated that the capacity 
for dipeptide transport is present in both the proximal and distal small intestine, with the colon 
potentially being able to transport peptides during the suckling state.  By post-weaning, the ileum 
is the site of highest dipeptide uptake.  The importance of dipeptides to the nutritional status of 
the developing infant is still unknown; however, when therapeutic formulas are necessary, it is 
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likely that the provision of all or part of the nitrogen as small peptides conveys advantages over 
preparations of free amino acids, and this may be of particular importance when compromised 
intestinal function is present. 
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Chapter 3:Enterally delivered dipeptides induce 
changes in small intestinal morphology in a piglet 
model of intestinal resection 
 
The work presented in this chapter was funded in part by a grant from the Ajinomoto 
Amino Acid Research Program.  It represents work that was presented at Experimental Biology 
2011 in Washington, D.C., U.S.A and will be submitted for publication in Clinical Nutrition.  
The co-authors of this work are Matthew G. Nosworthy, M. Elaine Dodge, Robert F. Bertolo and 
Janet A. Brunton.  All authors were responsible for designing the study and conducting the 
surgeries, MGN carried out the laboratory analysis with assistance from MED with respect to the 
western blots and BrdU, MGN performed the statistical analyses. 
Intestinal resection is an important issue in neonates leading to a reduction in absorptive 
capacity, with 2.2% of neonatal intensive care unit admissions resulting in short bowel 
syndrome, a condition with a 37.5% fatality rate.  As PepT1 is preferentially maintained over 
free amino acid transporters during gut stress, provision of dipeptides would result in increased 
nutrient availability thereby potentially enhancing the adaptive response of a surgically shortened 
intestine.  By selecting the dipeptides cysteinyl-glycine and alanyl-glutamine as test dipeptides, 
this study also established whether these dipeptides were beneficial in inducing adaptation in a 
piglet model of short bowel syndrome.    
Hypothesis: Dipeptides (alanyl-glutamine, cysteinyl-glycine, alanyl-alanine) delivered into a 
surgically shortened gut will induce an increase in PepT1 mRNA and protein in the residual 
intestine.  Greater efficiency of uptake of glutamine and cysteine as dipeptides (compared to 
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alanyl-alanine or free amino acids) will result in structural and functional enhancements of the SI 
mucosa, greater rates of mucosal protein synthesis and improved redox status. 
3.1 Abstract 
PepT1, a di/tripeptide transporter, is preferentially maintained over free amino acid transporters 
in situations of gut stress.  Therefore our objective was to determine the impact of enterally 
delivered dipeptide-containing diets on indices of intestinal adaptation in neonatal piglets after 
intestinal resection. 
Methods:  Piglets (N = 25, 10 ± 1 d old) underwent an 80% jejuno-ileal resection and were 
randomized to either 1) a control diet containing free amino acids, or the same diet but with 
equimolar amounts of free amino acids replaced by 2) alanyl-alanine, 3) alanyl-glutamine , 4) 
cysteinyl-glycine or 5) both alanyl-alanine and cysteinyl-glycine.  Outcome measures included 
plasma and mucosal amino acid concentrations, morphological and histological differences in the 
remnant intestine, PepT1 mRNA and protein expression, and mucosal cytokine concentrations. 
Result:  Intestinal length, organ weight and protein synthesis rates were similar between groups 
after 4 d of enteral feeding.  All of the dipeptide-containing diets reduced pro-inflammatory 
cytokine concentrations in the mucosa (TNF-α, IFN-γ).  The cysteinyl-glycine diet supported 
greater villus height compared to all other dipeptides and greater crypt depth compared to alanyl-
glutamine; however, none of the dipeptide diets altered intestinal morphology compared to the 
free amino acid control diet.   
Conclusions: This study showed that while there was no explicit morphological benefit of enteral 
dipeptides over their constituent free amino acids, there was the potential for the amelioration of 
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intestinal inflammation by reducing pro-inflammatory cytokines.  Enteral provision of dipeptides 
impacted intestinal adaptation, but the response was dipeptide-specific. 
3.2 Introduction  
Peptide transporter 1 (PepT1) is responsible for absorption of small peptides, two or three 
residues, from the lumen of the small intestine.  Increasing evidence suggests that PepT1 
population and/or activity can be altered by manipulating the nutritional status or health of the 
animal (Daniel, 2004). In situations of gut stress such as malnutrition, intestinal failure or 
surgical intervention, PepT1 expression is maintained or increased, in contrast with other nutrient 
transporters which typically decline in number (Satoh et al., 2003).  Humans fasted for 14 days 
demonstrated a significant decrease in the transport of amino acids but peptide transport was 
maintained (Vazquez et al., 1985). Ihara et al. (Ihara et al., 2000) reported a 179% increase in 
PepT1 mRNA over control samples in the jejunum of rats after a 4 day fast.  In addition to being 
preserved during gut stress, PepT1 expression is also substrate driven.  The presence of 
exogenous peptides in the culture media resulted in an increase in PepT1 expression in Caco-2 
cells (Walker et al., 1998).  Dietary provision of peptides has also demonstrated the same result 
in rats (Erickson et al., 1995, Shiraga et al., 1999). When the uptake of dietary protein is 
compromised due to intestinal injury such as inflammation or surgery, it may be advantageous to 
provide small peptides rather than free amino acids in the diet, to stimulate the population of 
PepT1 at the brush border and exploit the capacity for nitrogen transport.  
Short bowel syndrome (SBS) is a clinical condition induced through the surgical removal 
of intestinal tissue.  Causes for intestinal resection are varied, and include inflammatory 
disorders such as Crohn’s disease and colitis, tumors, physical trauma and infection such as 
necrotizing enterocolitis (NEC) (Goulet et al., 1991).  Intestinal resection results in a loss of 
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absorptive capacity (Sukhotnik et al., 2002) leading to a requirement for long term parenteral 
nutrition (PN).  In newborn and pre-term infants, SBS is commonly the result of congenital 
malformations or NEC (Sodhi et al., 2008). NEC is an aggressive, anaerobic infection that 
develops rapidly in the gastrointestinal tract in approximately 10% of all very low birth weight 
infants, with up to a 34% mortality rate in the lowest birth weight category (Fitzgibbons et al., 
2009).   
A recent study conducted in my supervisors lab demonstrated that enteral feeding (EN) of 
an elemental diet in combination with PN, induced intestinal adaptation in a piglet model of 
SBS.  This led to greater cell mass and intestinal length compared to PN alone (Dodge et al., 
2012).    Due to the substrate driven expression of PepT1, we hypothesized that providing enteral 
amino acids as peptides may stimulate the up-regulation of PepT1, leading to greater amino acid 
transport potential. 
Certain amino acids such as glutamine and cysteine are involved in intestinal barrier 
function and the regulation of oxidative stress.  Glutamine may be necessary for the localization 
of tight junction proteins in Caco-2 cells, thereby linking glutamine directly to intestinal integrity 
(Li et al., 2004).  Decline in the B0 transporter after surgical resection (Satoh et al., 2003) may 
prevent adequate absorption of glutamine, which could interfere with the maintenance of the 
intestinal barrier.  With PepT1 potentially up-regulated following surgery, and single amino acid 
transporters possibly depressed, the provision of enteral glutamine as a dipeptide may be 
particularly advantageous to the remaining intestine. 
Cysteine is a conditionally essential amino acid as it can be synthesized via trans-
sulfuration from methionine.  Cysteine has been linked to increased cellular proliferation via 
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transition from the G1 phase to S phase of the cell cycle (Noda et al., 2002).  Piglets that were 
fed an enteral diet free of sulfur amino acids presented with intestinal atrophy as demonstrated 
by reduced cellular proliferation, lower numbers of goblet cells and reduced villus height 
(Bauchart-Thevret et al., 2009).  Cysteine is also one of the amino acid residues in glutathione (-
Glu-Cys-Gly, GSH), and contributes to controlling cellular redox states (Wu et al., 2004). 
Limiting the availability of cysteine led to lower concentrations of glutathione in the plasma and 
intestinal mucosa of rats (Nkabyo et al., 2006). Studies in humans with inflammatory bowel 
disorders requiring surgical resection have demonstrated compromised redox status (Sido et al., 
1998).  Inclusion of cysteine-containing peptides in enteral diets may enhance cysteine 
availability and increase the generation of GSH, leading to improved recovery and intestinal 
adaptation. 
In this study we utilized a Yucatan miniature piglet model of intestinal adaptation which 
was previously characterized in my supervisors laboratory (Dodge et al., 2012) to investigate the 
potential benefits of alanyl-glutamine and cysteinyl-glycine when provided enterally to piglets 
with an 80% proximal resection of the small intestine.    
3.3 Materials and Methods 
 
3.3.1 Surgical procedures  
 
 Twenty-five (25) Yucatan miniature piglets, 10-12 days of age, were obtained 
from a breeding herd at Memorial University of Newfoundland (St John’s, NL) and randomized 
to one of five experimental groups. All experimental procedures were approved by the 
Institutional Animal Care Committee in accordance with guidelines of the Canadian Council of 
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Animal Care. Anesthesia was induced with an intramuscular injection of ketamine hydrochloride 
(22 mg/kg; Bimeda Canada, Cambridge, ON) and acepromazine (0.5 mg/kg; Vetoquinol Canada 
Inc, Lavaltrie, QC). After atropine sulfate injection (0.05 mg/kg; Rafter Dex Canada, Calgary, 
AB), the piglets were intubated and maintained under anesthesia with 1.0 - 1.5% isoflurane 
(Abbott Laboratories Ltd, Montreal, QC) mixed with oxygen at a flow rate of 1.5 L/min. In each 
piglet, 2 venous catheters were surgically implanted. One catheter was introduced into the 
femoral vein and advanced to the inferior vena cava for blood sampling and drug delivery. A 
second catheter was introduced into the jugular vein and advanced to the superior vena cava for 
the delivery of parenteral nutrition. The abdomen was opened, and approximately 80% of the 
proximal SI was resected, leaving 100 cm of the distal ileum proximal to the ileocecal valve 
intact. Continuity of the SI was restored using an end-to-end anastomosis.  Animals also 
underwent implantation of a gastric catheter to allow for infusion of the enteral diet. 
After surgery, piglets received intravenous antibiotics (20 mg of trimethoprim and 100 
mg of sulfadoxine; Borgal, Intervet Canada Ltd, Kirkland, ON) and analgesic (0.03 mg/kg of 
buprenorphine hydrochloride; Temgesic, Schering-Plough, Kirkland, ON).  Borgal was given 
daily and Temgesic every 12 h for the first 3 days postoperatively. Piglets were fitted with 
jackets secured to a tether-swivel system with dual-infusion ports (Lomir Biomedical, Notre-
Dame-De-L'Ile-Perrot, QC), allowing for the continuous infusion of both parenteral and enteral 
fluids. Piglets were housed in individual circular metabolic cages (1 m diameter), which allowed 
visual and aural contact with other piglets; toys were also provided. Lighting was maintained on 
a 12-h light:dark cycle, and room temperature was maintained between 23°C and 28°C with 
supplemental heat provided by heat lamps. Piglet weights were taken daily beginning 48 h after 
surgery.  
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3.3.2 Parenteral/Enteral Diets 
 
Following surgery, infusion of parenteral diet was initiated via the jugular vein at 50% of 
targeted intake. On the morning of day 1, the rate of infusion was increased to 75% for 12 h and 
then to 100% by the end of day 1 (13.5 mL·kg
–1
·d
–1
).  The complete parenteral diet provided 1.1 
MJ of metabolizable energy·kg
–1
·d
–1 
with glucose (24.5 g·kg
–1
·d
–1
) and lipid (20% Intralipid, 
Pharmacia, Stockholm, Sweden) each supplying 50% of non-protein energy and 15 g·kg
–1
·d
–1
 of 
protein, supplied as free amino acids. The amino acid composition was as follows (per gram of 
total L-amino acids): alanine, 107 mg; arginine, 67 mg; aspartate, 61 mg; cysteine, 14 mg; 
glutamate, 105 mg; glycine, 27 mg; histidine, 31 mg; isoleucine, 46 mg; leucine, 104 mg; lysine-
HCl, 102 mg; methionine, 19 mg; phenylalanine, 55 mg; proline, 83 mg; serine, 56 mg; taurine, 
5 mg; threonine, 41 mg; tryptophan, 21 mg; tyrosine, 8 mg; and valine, 53 mg (Dodge et al., 
2012). Prior to feeding, vitamins (Multi-12K1 Pediatric, Sabex Boucherville,  QC), trace 
minerals, 200% of NRC recommendations, (NRC, 1998), lipid, and iron dextran (Fe, 3.0 mg/kg; 
Vetoquinol Canada Inc, Lavaltrie, QC) were added to the diet. On day 2, the presence of ileus 
was tested by infusing a 10-mL bolus of the complete parenteral diet into the stomach via the 
gastric catheter. If gastric emptying was evident, then enteral feeding was initiated on day 3, and 
increased over the following 24 h to achieve 50% of total nutritional intake with the balance 
being maintained via parenteral nutrition. The diets were continuously infused intravenously and 
enterally by pressure sensitive peristaltic pumps. 
The piglets were randomized to one of 5 experimental enteral diets (N = 5 per group). 
The experimental diets were based on the elemental diet used for parenteral nutrition, with the 
majority of the nitrogen provided as free L-amino acids.  The dietary manipulations included 1) 
free amino acids as a control diet (CON), or the equimolar replacement of free amino acids with 
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the following dipeptides; 2) alanyl-alanine (AA), 3) alanyl-glutamine (AQ), 4) cysteinyl-glycine 
(CG) or 5) the combination of alanyl-glutamine and cysteinyl-glycine (AQ+CG) (Dipeptides 
were purchased from Bachem, Torrance, CA ).  All enteral diets were isonitrogenous. The amino 
acid composition of the enteral diets is given in Table 3.1. 
3.3.3 Necropsy and Tissue Collection 
 
Animals were injected intravenously with 50 mg/kg of 5-bromo-2′-deoxyuridine (BrdU) 
(Sigma Aldrich, Oakville, ON) 4 hours before necropsy.  Thirty minutes prior to necropsy 
animals were injected intravenously with 1.5 mmol/kg phenylalanine, of which 0.15 mmol/kg 
was labelled with 
3 
H-phenylalanine. At necropsy, the site of anastomosis was identified and the 
small intestine removed from the site of anastamosis to the ileocecal valve. The weight and 
length of this portion of the small intestine were measured and considered the “remnant 
intestine”.  A 3-cm segment of remnant intestine immediately distal to the site of anastomosis 
was also immersed in neutral buffered 10% formalin (Fisher Scientific, Pittsburgh, PA) for 
histologic analyses. The following 50 cm of remnant intestine was isolated and weighed, and the 
mucosa was harvested from the this intestinal section which was slit longitudinally and placed on 
a glass plate on ice. The mucosal tissue was scraped from the underlying muscle using a glass 
slide with even pressure, weighed and flash frozen in liquid nitrogen.  Liver and kidney weights 
were also measured. 
3.3.4 Histological Analysis 
3.3.4.1 Preparation of Slides 
After fixation in 10% buffered formalin (Fisher Scientific, Pittsburgh, PA), samples of 
intestine were dehydrated in ethanol, cleared in xylene, embedded in paraffin wax, and sliced 
into 5-µm sections. 
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Table 3.1: Amino acid composition of the enteral diets (g/L) 
Amino Acid Control AA AQ CG AQ+CG 
 
alanine 4.4 0 1.03 4.4 1.03 
arginine 3.59 3.59 3.59 3.59 3.59 
aspartate 3.27 3.27 3.27 3.27 3.27 
cysteine 1.1 1.1 1.1 0 0 
glutamate 0 0 0 0 0 
glycine 1.47 1.47 1.47 0.8 0.8 
histidine 1.67 1.67 1.67 1.67 1.67 
isoleucine 2.48 2.48 2.48 2.48 2.48 
leucine 5.61 5.61 5.61 5.61 5.6 
lysine 5.58 5.58 5.58 5.58 5.58 
methionine 1.04 1.04 1.04 1.04 1.04 
phenylalanine 2.95 2.95 2.95 2.95 2.95 
proline 4.46 4.46 4.46 4.46 4.46 
serine 5.19 5.19 5.19 5.19 5.19 
taurine 0.24 0.24 0.24 0.24 0.24 
tryptophan 1.14 1.14 1.14 1.14 1.14 
tyrosine 0.42 0.42 0.42 0.42 0.41 
valine 2.86 2.86 2.86 2.86 2.86 
threonine 2.18 2.18 2.18 2.18 2.18 
glutamine 5.5 5.5 0 5.5 0 
alanyl-glutamine  0 0 8.87 0 8.87 
alanyl-alanine 0 4.4 0 0 0 
cysteinyl-glycine 0 0 0 1.77 1.77 
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3.3.4.2 Crypt Depth/Villus Height 
 
Sections were stained with hematoxylin and eosin (Fisher Scientific, Pittsburgh, PA). 
Villus height and crypt depth were measured with a Zeiss Axiostar microscope (Carl Zeiss 
Toronto, ON).  Images were captured with an Infinity 1 camera and Infinity Analyze software 
(Lumenera Corporation Nepean, ON) Ten measurements of villus height and crypt depth were 
performed per animal. All histological measurements were performed in a blinded manner by a 
single investigator (MGN), see figure 3.1 for a representative image. 
3.3.4.3 Cellular Proliferation Index Using 5-Bromo-2′-deoxyuridine 
 
Immunohistologic analyses were performed to measure incorporation of BrdU into 
proliferating cells of small intestinal crypts (BD Biosciences Pharmingen, Mississauga, ON ) 
with visualization based on DAB substrate (Vector Laboratories, Burlington, ON). Data were 
expressed as the number of cells labeled with BrdU per total number of cells in an individual 
crypt (10 crypts per animal). 
3.3.5 Tissue Protein Synthesis 
Fractional rates of protein synthesis were measured by infusing a flooding dose of labeled 
and unlabeled phenylalanine (Garlick et al., 1980). Briefly, 4 days after initiation of enteral 
feeding and 30 min prior to necropsy, piglets were given an i.v. bolus of 
3
H-phenylalanine (37 
MBq per kg body weight) in 150 mmol/L phenylalanine (10 mL/kg body weight). Thirty minutes 
after the initiation of the phenylalanine bolus, piglets were anesthetized, and samples of liver and 
mucosa from the remnant intestine were taken for analysis of rates of protein synthesis. Specific 
radioactivities of the tissue free phenylalanine and the protein-bound phenylalanine were 
determined as described previously (Brunton et al., 2012).   
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Figure 3.1 Representative image of remnant intestine villus height and crypt depth 
measurements.   
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3.3.6 Tissue and Plasma Amino Acid Determination  
 
Free amino acid concentrations in plasma and tissue samples were analyzed using PITC 
derivatization (Bidlingmeyer et al., 1984) with norleucine as the internal standard. Phenylalanine 
fractions were collected and the radioactivity associated with these fractions was determined by 
scintillation counting. 
3.3.7 Real-time RT-PCR 
 
PepT1 mRNA was measured in small intestinal mucosa.  RNA was extracted using the 
Qiagen RNEasy Mini kit (Qiagen Inc. Montréal, QC) according to the manufacturer’s protocol.  
Concentration, purity and integrity were determined via the Agilent RNA Nano chip (Agilent 
Technologies, Mississauga, ON).  cDNA was generated according to the protocol outlined in the 
QuantiTect (Qiagen Inc. Montréal, QC, Canada) reverse transcriptase manual. 800 ng of total 
RNA was used in the reverse transcription reaction. Roche Faststart DNA master Sybr Green I 
kit (Roche, Laval, QC) was used for the qPCR reaction.  The sequences of the primers were as 
follows: PepT1 forward primer 5’ d CTGGAGTTCTCCTATTCTCA 3’,  reverse primer 5’ d 
AACAGCCACGGTCAACAG 3’,  β-actin was used as an internal control with the following 
sequences: forward primer 5’ d CCCAGCACGATGAAGA 3’, reverse primer 5’ d 
CGATCCACACGGAGTC 3’.   The accession numbers for the template sequences were 
AY180903.1 for PepT1 (Klang et al. 2005) and AY55069 for beta-actin.  The qPCR machine 
(Eppendorf Mastercycler, Eppendorf Mississauga, ON) was set to the following conditions: 10 
min at 95°C, 40 cycles of 15 sec at 95°C and 15 at 58°C, and 63°C incubation for 15 sec.  
Reaction efficiency for PepT1 was 0.87 ± 0.04 and β-actin reaction efficiency was 0.89 ± 0.04. 
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Each sample was run in duplicate and analyzed using 2
-ddCt 
 method (Livak and Schmittgen, 
2001). 
3.3.8 PepT1 Protein Analysis 
 
3.3.8.1 Brush Border Membrane Vesicle (BBMV) Preparation  
 
Brush border membrane vesicles were isolated from mucosal scrapings.  Briefly, tissues 
were homogenized in 100 mM mannitol, 2 mM HEPES/Tris pH 7.1 and 0.1 mM PMSF and 2 
mL of the homogenate was removed for protein and marker enzyme analysis.  The remaining 
sample was centrifuged at 500 g for 12 min.  Then 1 M MgCl2 was added to the supernatant to a 
final concentration of 10 mM, this solution was incubated on ice for 20 minutes prior to 
centrifugation at 3,000 g for 15 min. The supernatant was collected and centrifuged at 30,000 g 
for 30 min.  The pellet was then resuspended in 20 ml of 100 mM mannitol, 2 mM HEPES/Tris 
pH 7.4 and 1 mM MgSO4 and centrifuged at 30,000 g for 30 min to isolate BBMV’s.  The final 
pellet was resuspended in 300 mM mannitol, 20 mM HEPES/Tris pH 7.4 and 0.1 mM MgSO4 
(400 µl/g of wet tissue) and stored at -80°C. 
3.3.8.2 Western Blot 
 
  BBMV’s were analyzed for protein content using the BCA protein assay (Pierce 
Chemicals, Rockford, IL). Equivalent amounts of protein (50 μg) were electrophoresed on 8% 
SDS-polyacrylamide gels. After transfer to nitrocellulose membrane, blots were stained with 
Ponceau Red (Sigma Aldrich, Oakville, ON) to assess the equivalency of protein loading. Blots 
were blocked in 3% milk-TBST (Tris-buffered saline and Tween 20 at 0.2% V/V) for 45 min at 
room temperature and incubated with primary antibodies overnight at 4 °C. Primary antibodies 
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used were PepT1 (rabbit polyclonal 1:600, gift provided by E.A. Wong, Department of Animal 
and Poultry Sciences, Virginia Tech, Blacksburg, VA), and β-Actin (1:600 Sigma Aldrich, 
Oakville, ON). Blots were visualized using the Immun-Star WesternC Kit (Bio Rad, Montreal, 
QC) and images obtained using aa Alpha Innotech Chemiimager Gel Documentation System. 
 Band intensity was analyzed using AlphaVIEW SA (ProteinSimple, Toronto, ON) and PepT1 
expression was assessed relative to β-actin for each sample.  
3.3.8.3 Sucrase Enrichment of Brush Border Membrane Vesicles  
 
Brush border membrane vesicles (BBMV’s) were analysed for sucrase enrichment as per 
Dahlqvist (1968). In brief, 40 µg of protein from tissue homogenate or BBMV’s were incubated 
with 0.056 M sucrose at 37 °C for 20 min in triplicate. One triplicate was heat inactivated via 
immersion in boiling water for 5 min prior to incubation (blank).  After incubation an assay 
reagent consisting of o-Dianisidine, glucose oxidase and peroxidase (Sigma Aldrich, Oakville, 
ON) was added to each sample and incubated for an additional 20 min at 37 °C.  The enzymatic 
reaction was stopped by boiling the samples for 5 min.  The absorbance of the resulting solution 
was measured at 420 nm in a BioMate 3 spectrophotometer (Fisher Scientific, Pittsburgh, PA) 
and total glucose release was calculated through comparison to a standard curve after subtraction 
of the sample blank.  Overall sucrase enrichment was calculated by the ratio of sucrose release 
per µg of total protein from BBMV suspension to that of the tissue homogenate.   
3.3.9 Tissue and plasma glutathione  
 
Plasma and intestinal tissue concentrations of reduced and total glutathione were 
measured using the Biovision Glutathione assay kit (Biovision, Milpitas, CA) according to their 
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protocol.  In brief, 60 µl of plasma was deproteinized via the addition of 20 µl of perchloric acid.  
This mixture was centrifuged at > 10,000 g for 2 minutes at 4 ˚C and 10 µl of the supernatant 
was added to the microplate.   Assay buffer was used to increase the sample volume to either 90 
µl to measure reduced glutathione or 80 µl + 10 µl of reducing reagent to detect total glutathione.  
10 µl of the o-phthalaldehyde probe was added to each well and incubated at room temperature 
for 40 min.  Plates were read in a Powerwave XS microplate reader (Biotek, Winooski, VT) with 
Ex/Em=340/450.  Concentration of GSSG was calculated by subtracting the concentration of 
GSH from the total glutathione concentration.  
3.3.10 TNF-α and IFN- 
 
Mucosal TNF-α and IFN- concentrations were determined via porcine ELISA kits 
(Pierce, Rockford, IL).  The kits utilized anti-human antibodies that cross react with porcine 
cytokines.  Tissue supernatants were prepared by homogenizing tissue in PBS containing 
Protease Inhibitor Cocktail III (Calbiochem, San Diego, CA) and 1 mM PMSF (Sigma Aldrich, 
Oakville, ON).  Homogenates were then centrifuged at > 10,000 g for 5 minutes at 4 ˚C to allow 
for analysis of tissue supernatants according to the protocol provided by the supplier.  
Absorbance of the enzyme-substrate product was determined by subtracting the calculated value 
at 550 nm from that determined at 450 nm.  Linear regression was used to calculate the final 
concentration of cytokine in the supernatant which was reported as concentration per gram of 
mucosa.  
3.3.11 Statistics 
 
All results were expressed as mean ± standard deviation for each group of animals.  Data 
were analyzed by one-way ANOVA with Bonferroni’s protected means separation test. Sample 
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size was N = 5 piglets per dietary treatment and differences were noted as significant if p < 0.05 
(GraphPad Prism 4.0, La Jolla, CA). 
3.4 Results 
3.4.1 Morphologic measurements  
 
Body weights did not differ amongst treatment groups  (initial: 2.23 ± 0.30 kg; final 
control 3.27 ± 0.46 kg, AA 3.28 ±  0.26 kg, AQ 3.20 ± 0.49 kg, CG 2.85 ± 0.32 kg,  AQ+CG 
3.42 ± 0.38 kg).  Also, no differences were found in weight gain per kilogram per day 
(determined for the period after initiation of EN), and the percentage increase in body weight 
was similar among all treatment groups (Table 3.2).  No significant differences were determined 
in plasma amino acid concentrations amongst treatment groups (Table 3.3).  At necropsy, total 
liver and kidney weights were also not different amongst treatment groups (Table 3.2).  Protein 
synthesis rates in the liver and intestinal mucosa were also similar across dietary treatments 
(Table 3.2).  Length of the remnant intestine increased in all groups after one week of enteral 
feeding (Table 3.2).   
There was no effect of diet on the total weight in the remnant small intestine (Table 3.2), 
but the alanyl-glutamine and AQ+CG treatment resulted in lower mucosa weight in the proximal 
50 cm of the remnant intestine when compared to the control diet (Figure 3.2).    
3.4.2 Histology 
 
Analysis of intestinal morphology was performed on sections taken distal to the site of 
anastomosis (Figure 3.3).  Villus height was similar between CG and control treatments (CG:  
906 ±119 µm, control: 801 ± 49 µm); however villus height in the CG group was significantly  
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Table 3.2: Comparison of morphological and metabolic changes in piglets receiving 
different enteral diets. 
 
 Control AA AQ CG AQ+CG 
Remnant 
Intestinal 
Length (cm) 
185 ± 21 196 ± 15 170 ± 36 174 ± 31 180 ± 25 
Remnant 
Intestinal 
Weight 
(g/cm) 
0.31 ±  0.07 0.23 ± 0.04 0.26 ± 0.08 0.31 ± 0.10 0.28 ± 0.09 
Kidney 
Weight (g/kg) 
3.67 ± 0.41 3.54 ± 0.72 4.40 ± 0.89 4.37 ± 0.75 3.70 ± 0.38 
Liver Weight  
(g/kg) 
37.36 ± 3.89 38.85 ± 3.71 40.14 ± 7.00 41.77 ± 7.92 38.26 ± 2.54 
Mucosal 
Protein 
Synthesis 
(%/day) 
78 ± 27 90 ± 13 85 ± 23 98 ± 14 83 ± 14 
Liver Protein 
Synthesis 
(%/day) 
114 ± 38 71 ± 19 75 ± 30 88 ± 35 80 ± 14 
 
N = 5 piglets per group, values are mean ± SD.   
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Table 3.3: Plasma Amino Acid Concentrations (µmol/L) 
Amino Acid Control AA AQ CG AQ+CG 
Alanine 455 ± 100 543 ± 57 515 ± 57 572 ± 54 484 ± 122 
Arginine 126 ± 34 118 ± 32 134 ± 40 94 ± 24 137 ± 38 
Aspartate 25 ± 12 23 ± 11 25 ± 8 32 ± 19 18 ± 7 
Cysteine 260 ± 35 229 ± 52 285 ± 62 226 ± 59 229 ± 53 
Glutamate 161 ±  62 192 ± 60 201 ± 51 217 ± 75 150 ± 55 
Glutamine 230 ± 40 205 ± 63 224 ± 31 245 ± 70 233 ± 22 
Glycine 920 ± 302 927 ± 245 985 ± 213 961 ± 228 970 ± 496 
Isoleucine 148 ± 21 171 ± 12 164 ± 37 167 ± 20 150 ± 45 
Leucine 286 ± 47 280 ± 88 262 ± 94 273 ± 61 284 ± 50 
Lysine 370 ± 71 330 ± 185 392 ± 168 410 ± 196 365 ± 98 
OH-Proline 64 ± 11 66 ± 25 48 ± 18 67 ± 22 58 ± 7 
Phenylalanine 181 ± 44 182 ± 27 190 ± 32 175 ± 8 182 ± 57 
Proline 510 ± 80 500 ± 98 528 ± 110 549 ± 87 513 ± 83 
Serine 480 ± 87 476 ± 34 450 ± 53 509 ± 98 443 ± 65 
Taurine 143 ± 20 154 ± 49 137 ± 18 161 ± 21 132 ± 50 
Threonine 245 ± 48 221 ± 6 227 ±24 319 ± 95 230 ± 61 
Valine 267 ± 39 315 ± 51 248 ± 66 257 ± 49 269 ± 69 
 
 
N = 5 piglets per group, values are mean ± SD.   
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Figure 3.2:  Weight of mucosa from the proximal 50 cm of the remnant intestine in piglets fed 
diets containing either all free amino acids (Control), or one of alanyl-alanine (AA), alanyl-
glutamine (AQ), cysteinyl-glycine (CG) or both AQ and CG (AQ+CG).  N = 5 piglets per group, 
values are mean ± SD.  Data were analyzed by 1-way ANOVA with Bonferroni’s protected 
means separation test for post hoc analysis.  Bars with differing letters are significantly different 
p < 0.05. 
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Figure 3.3: Villus height and crypt depth distal to the site of anastamosis in piglets fed diets 
containing either all free amino acids (Control), or one of alanyl-alanine (AA), alanyl-glutamine 
(AQ), cysteinyl-glycine (CG) or both AQ and CG (AQ+CG).  N = 5 piglets per group, values are 
mean ± SD.  Data were analyzed by 1-way ANOVA with Bonferroni’s protected means 
separation test.  Bars with differing letters are significantly different p < 0.05. 
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Figure 3.4: BrdU incorperation into the intestinal crypts of piglets fed diets containing either all 
free amino acids (Control), or one of alanyl-alanine (AA), alanyl-glutamine (AQ), cysteinyl-
glycine (CG) or both AQ and CG (AQ+CG).  Data are presented as percent of total cells labelled 
with BrdU.  N = 5 piglets per group, values are mean ± SD.   
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higher than any other dipeptide group (p < 0.05) (Figure 3.2).  Enteral CG also resulted in 
significantly greater crypt depth when compared to AQ (CG 154 ± 11 µm vs AQ 116 ± 13 µm) 
(p < 0.05) (Figure 3.3).  Provision of enteral dipeptides did not alter cellular proliferation, as 
determined by BrdU incorporation (Figure 3.4).  
3.4.3 GSH, TNF-α and IFN- 
 
Total and reduced glutathione was quantified in both plasma and mucosal tissue (Figure 
3.5); no significant differences amongst treatments were detected.  The inclusion of AQ or CG, 
or both, in the enteral diets significantly reduced the concentration of IFN- to less than 40% of 
control (p < 0.05) (Figure 3.6).  The inclusion of any of the dipeptides in the diets resulted in a 
dramatic reduction in TNF-α, to less than 27% of control (p < 0.01) (Figure 3.7) 
3.4.4 PepT1 mRNA/Protein Expression 
 
Samples of mucosa taken from the remnant intestine were used to determine PepT1 
mRNA and protein expression. No significant difference was found in PepT1 mRNA (Figure 
3.8) or protein expression (Figure 3.10) between any of the dietary regimens.   
3.5 Discussion  
 
In a previous study (Dodge et al., 2012), it was demonstrated that early provision of an 
elemental enteral diet in tandem with parenteral nutrition resulted in massive adaptive responses 
in a piglet model of short bowel syndrome.  We used this model to investigate potential trophic 
effects of dipeptides, some of which were composed of metabolically important amino acids.  
The most intriguing outcome was the substantial influence of dipeptides on the mucosal 
concentration of pro-inflammatory cytokines. Surprisingly, in contrast to this observation, the  
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Figure 3.5:  Total (white bar) and reduced (patterned bar) glutathione concentrations in plasma 
(a) and mucosa (b) in piglets fed diets containing either all free amino acids (Control), or one of 
alanyl-alanine (AA), alanyl-glutamine (AQ), cysteinyl-glycine (CG) or both AQ and CG 
(AQ+CG).  N = 5 piglets per group, values are mean ± SD. Data were analyzed by 1-way 
ANOVA.   
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Figure 3.6: Concentration of IFN- in intestinal mucosa of piglets fed diets containing either all 
free amino acids (Control), or one of alanyl-alanine (AA), alanyl-glutamine (AQ), cysteinyl-
glycine (CG) or both AQ and CG (AQ+CG). N = 5 per group.  Values are mean ± SD.  Data 
were analyzed by 1-way ANOVA with Bonferroni’s protected means separation test for post-hoc 
analysis.  Bars with differing letters are significantly different p < 0.05. 
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Figure 3.7: Concentration of TNF-α in intestinal mucosa of piglets fed diets containing either all 
free amino acids (Control), or one of alanyl-alanine (AA), alanyl-glutamine (AQ), cysteinyl-
glycine (CG) or both AQ and CG (AQ+CG). N = 5 per group.  Values are mean ± SD.  Data 
were analyzed by 1-way ANOVA Bonferroni’s protected means separation test for post-hoc 
analysis.  Bars with differing letters are significantly different p < 0.05. 
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Figure 3.8: Fold change of PepT1 mRNA in intestinal mucosa of piglets fed diets containing 
either all free amino (Control), or one of alanyl-alanine (AA), alanyl-glutamine (AQ), cysteinyl-
glycine (CG) or both AQ and CG (AQ+CG). N = 5 per group.  Values are mean ± SD.   
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Figure 3.9: Representative western blot of PepT (top) and β-actin (bottom).  Circled bands were 
selected for analysis on the basis of anticipated size.  Lanes are as follows: AA, AQ+CG, CG, 
AQ and control.  
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Figure 3.10: Ratio of PepT1 protein to β-actin in intestinal mucosa of piglets fed diets containing 
either all free amino acids (Control), or one of alanyl-alanine (AA), alanyl-glutamine (AQ), 
cysteinyl-glycine (CG) or both AQ and CG (AQ+CG). N = 5 per group.  Values are mean ± SD.   
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data also suggest that inclusion of alanyl-glutamine in the enteral diet may actually be 
detrimental to mucosal growth in this surgical model.   
Differences in the cytokine concentrations in mucosa isolated from piglets demonstrate 
that the form of the dietary amino acids can alter the inflammatory state of the small intestine.  
Small intestinal bacterial overgrowth is a common and potentially serious complication of short 
bowel syndrome in infants that dramatically increases the risk of systemic infection (Cole et al., 
2010).  In a study of 10 infants with SBS, the concentration of circulating pro-inflammatory 
cytokines was inversely correlated with enteral intake; however, the form of the enteral diets was 
not described (Cole et al., 2010).  In our study, mucosal IFN- concentration was lower than 
control in the treatment groups that received CG, AQ or both, but not in the group fed AA.  
Thus, there is an underlying mechanism at work that responds to specific dipeptides.  The impact 
of alanyl-glutamine on intestinal health has been studied in vitro using cell culture (Alteheld et 
al., 2005), in vivo via PN infusion into piglets (Burrin et al., 1994) and in a number of human 
trials that have employed both enteral and parenteral provision of this dipeptide (Eroglu, 2009, 
Luo et al., 2008, Lima et al., 2007). Parenteral provision of AQ has been shown to increase 
antioxidant capacity and plasma glutamine concentrations, while intraperitoneal injection of AQ 
reduced the number of IFN-  producing cells in a mouse model of DSS-induced colitis (Chu et 
al., 2012).  When provided as the free amino acid, enteral glutamine supressed pro-inflammatory 
cytokine production during an E. coli challenge in piglets (Ewaschuk et al., 2011); however the 
beneficial effect of enteral glutamine-containing dipeptides has yet to be established (Luo et al., 
2008, Eroglu, 2009, Ligthart-Melis et al., 2009).  We have demonstrated that while enteral AQ 
does reduce pro-inflammatory cytokines, it has no other significant benefits over provision of 
free amino acids. 
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Mucosal TNF-α was also dramatically lower in the dipeptide-treated piglets compared to 
the control group.  Unlike IFN-, however, the presence of any of the test dipeptides resulted in a 
reduction of TNF-α.  Bacterial peptides, substrates for PepT1, can induce a pro-inflammatory 
cytokine response in monocytes through NFκβ signalling (Pan et al., 2010).  l-Ala--d-Glu-meso-
DAP (Dalmasso et al., 2010) and formyl-methionyl-leucyl-phenylalanine (Shi et al., 2006b, 
Carlson et al., 2007) are examples of bacterially derived pro-inflammatory substrates for PepT1. 
NF-κβ is a ubiquitous transcription factor and is highly involved in regulation of the immune 
system and its activation requires the phosphorylation and subsequent degradation of its 
inhibitor, Iκβ (Baeuerle and Henkel, 1994).  Once active, NF-κβ can act on the promoter region 
for pro-inflammatory cytokines such as TNF- (Baeuerle and Henkel, 1994) and IFN- (Sica et 
al., 1997).  TNF- is also capable of stimulating activation of NF-κβ by activating Iκβ kinase, 
the enzyme responsible for marking Iκβ for degradation. This can result in a positive feedback 
loop and the propagation of the inflammatory response (Grell et al., 1995).  Interestingly, both 
thiols such as n-acetyl-cysteine, and glutamine are capable of blocking NFκβ activation 
(Singleton et al., 2005,). The mechanism by which thiols prevent NFκβ activation is believed to 
be the prevention of Iκβ degradation, either through the improper folding of required kinases or 
other inhibition of Iκβ phosphorylation (Staal et al., 1990).  For TNF-, it is possible that the 
dipeptide effect of competitive inhibition for fMLP transport reduced NFκβ activation by the 
bacterial peptide, subsequently resulting in reduced transcription of the cytokine.  Conversely for 
IFN-, the lower concentration of IFN- found in AQ, CG and AQ + CG animals may be due to 
the presence of thiols, in the form of CG, or glutamine, in the form of AQ.  These compounds 
could have disrupted the phosphorylation of Iκβ, with the similar result of preventing the 
activation of NFκβ and IFN- transcription.  
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In Caco-2 cells, supplementation of the media with IFN- resulted in an increased mRNA 
expression of PepT1 (Foster et al., 2009, Vavricka et al., 2006). This was not reflected in our 
findings as PepT1 mRNA concentration was not altered despite differing concentrations of IFN-
.  Similarly, previous work demonstrated the capacity for substrate induced expression of PepT1 
in Caco-2 cells and increased mRNA in a rodent model (Walker et al., 1998, Shiraga et al., 
1999).  We did not detect any differences in either PepT1 mRNA or protein among any of the 
dietary regimens.  Whether this is due to a lack of stimulation of PepT1 mRNA transcription, a 
reduction in protein trafficking to the brush border, or a missed temporal window of enterocyte 
response is undetermined. 
An interesting finding of this study was that both cysteinyl-glycine and free amino acids 
demonstrated structural advantages over alanyl-glutamine.  It is possible that enteral glutamine is 
less accessible for use by the intestine as a dipeptide due to inefficient intracellular hydrolysis, 
and that alanyl-glutamine is exported intact into the circulatory system. A comparative study of 
enteral versus parenteral alanyl-glutamine in critically ill patients revealed that plasma glutamine 
was higher when the dipeptide was provided parenterally (Luo et al., 2008). Other studies 
determining organ specific removal of dipeptides from human plasma reported that the intestine 
was responsible for removing only 13% of alanyl-glutamine present in the plasma (Reviewed in 
Vazquez et al., 1993). When glycyl-leucine and glycyl-glycine were assayed, it was found that 
the intestine was responsible for contributing the lowest rate of plasma clearance compared to the 
other tissues studied.  This indicates that the intestine does not significantly utilize circulating 
dipeptides compared to other tissues.  Although enterocytes are able to utilize plasma glutamine, 
the intestine preferentially utilizes enteral glutamine compared with intravenously provided 
glutamine for arginine synthesis (Ligthart-Melis et al., 2009).  If alanyl-glutamine is being 
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transported into the circulatory system intact, the glutamine would be less accessible for use by 
the intestine and therefore not the best form of glutamine for an injured gut.  
We ascertained that supplementation with either free cysteine or cysteinyl-glycine did not 
affect the concentration of cysteine in either plasma or intestinal mucosa.  This is similar to the 
findings of Shyntum et al. who determined that the plasma pool of cysteine was not modulated 
through dietary intake in a rat model of bowel resection (Shyntum et al., 2009).  Mucosal and 
plasma glutathione concentrations were similarly unaffected by altering the enteral diets 
potentially due to the fact that no difference in amino acid availability was determined.  Cysteine 
alone is part of the oxidative stress control system; however, it is also an essential part of 
glutathione (GSH), the primary regulator of oxidative stress (Jones, 2006).  Nkabyo et al. 
demonstrated greater redox potential with sulphur amino acid (SAA) supplementation (218% of 
control diet SAA) in a model of bowel resection in rats (Nkabyo et al., 2006).  Although this 
demonstrated that SAA supplementation results in an improved redox status, we have not 
demonstrated any additional advantages in redox status of this surgical model when cysteine was 
supplied as the dipeptide cysteinyl-glycine.  It is possible that supplementing with additional CG 
rather than providing only the nutritional requirements of cysteine as a dipeptide could have led 
to greater redox potential in our model.  Additionally, the bioavailability of this dipeptide to 
enterocytes, or lack thereof, is also a potential reason for the lack of response in our model.  
In this study, enteral dipeptides had no impact on protein synthesis or intestinal length 
when compared to free amino acids.  Piglets receiving CG had significantly greater villus height 
compared with either AQ or AQ+CG, and the CG treatment also resulted in greater crypt depth 
when compared to piglets receiving AQ.  However, there was no detectable difference in cellular 
proliferation at necropsy.  This discrepancy between the morphological data and cellular growth 
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data could be due to the time at which the samples were taken for analysis.  In this model, 
samples were removed approximately one week after surgery.  Previous work in our lab (Dodge 
et al., 2012) using an identical surgical model demonstrated that within 24 h of initiating enteral 
feeding there is a period of rapid cellular proliferation and a high rate of protein synthesis, that 
was not detectable one week later.  This study determined potential adaptive benefits of enteral 
dipeptides and therefore necessitated extended enteral feeding before necropsy; therefore it is 
likely that the period of rapid cellular proliferation occurred prior to sample removal. 
An important aspect to consider in this study is the bioavailability of these dipeptides.  
Stability and clearance of plasma cysteinyl-glycine have not been as clearly delineated as alanyl-
glutamine.  However, as CG is a product of GSH degradation, numerous peptidases such as 
leucyl amino peptidase and alanyl peptidase have been shown to hydrolyse CG (Cappiello et al., 
2004).  Certain characteristics of dipeptides may predict their affinity for transport via PepT1.  A 
study by Vig et al. detailed the effect of peptide size, hydrophobicity, composition and charge on 
dipeptide transport (Vig et al., 2006).  Although cysteine containing dipeptides were not used in 
that study, the results can be used to make inferences regarding the bioavailability of cysteinyl-
glycine.  All X-glycine dipeptides were transported via PepT1 and neutral dipeptides resulted in 
greater transport than charged peptides thereby suggesting that CG is a viable substrate for 
PepT1. 
The objective of this study was to determine the impact of enteral dipeptides on indices 
of intestinal adaptation in a piglet model of short bowel syndrome.  Enteral dipeptides induced a 
marked reduction in pro-inflammatory cytokines when compared to free amino acids, while there 
was no effect on either PepT1 mRNA or protein expression.  These results demonstrated that 
while there was no explicit morphological benefit of enteral dipeptides over their constituent free 
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amino acids, there is the potential for the amelioration of intestinal inflammation by reducing 
pro-inflammatory cytokines.   
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Chapter 4: Cysteinyl-glycine reduces mucosal pro-
inflammatory cytokine response to fMLP in a piglet 
model of intestinal atrophy. 
 
The work presented in this chapter was funded in part by a grant from the Canadian 
Institutes of Health Research.  This work was presented at Experimental Biology 2013 in Boston, 
MA, U.S.A and will be submitted for publication in the Journal of Nutrition. The co-authors of 
this work are Matthew G. Nosworthy and Janet A. Brunton.  MGN and JAB were responsible for 
designing the study, MGN carried out the animal work in addition to the laboratory and 
statistical analyses. 
Substrates for PepT1 are widely varied, including not only dietary peptides and 
peptidomimetic drugs but also bacterially produced peptides such a formyl-methionyl-leucyl-
phenylalanine (fMLP).  This peptide has been demonstrated to induce intestinal inflammation 
and is the primary chemotactic factor produced by Escherichia coli.  As parenteral nutrition 
increases both the risk of bacterial infection and PepT1 expression in the distal intestine, this 
study determined whether parenterally-fed neonatal piglets were more susceptible to fMLP-
induced inflammation than their sow-fed siblings.  Additionally, these experiments investigated 
whether the dipeptide cysteinyl-glycine could attenuate the inflammation stimulated by the 
bacterial peptide. 
 Hypothesis: Parenteral feeding will increase the susceptibility of the intestine to fMLP-
induced inflammation while inclusion of cysteinyl-glycine will ameliorate indices of 
inflammation in both dietary treatments to a greater extent than the free amino acids cysteine and 
glycine.  
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 4.1 Abstract  
PepT1 is an intestinal di/tripeptide transporter also capable of transporting bacterial 
peptides. We measured the mucosal inflammatory response to a pro-inflammatory peptide, 
formyl-methionyl-leucyl-phenylalanine (fMLP), when delivered with cysteinyl-glycine in a 
model of intestinal atrophy.  Pigs (N = 6, 10 d) received parenteral nutrition (PN) for 4 d to 
induce atrophy of the small intestine; littermates (N = 6) remained with the sow.  Subsequently, 
five 10 cm loops of the distal SI were isolated and perfused for 3 h with one of: 1) 5 mM 
cysteine  + 5 mM glycine 2) 5 mM cysteinyl-glycine 3) 10 µM  fMLP 4) 5 mM cys + gly + 10 
µM fMLP 5) 5 mM cysteinyl-glycine + 10 µM fMLP.  In both dietary treatments, intestinal 
segments exposed to fMLP had higher mucosal TNF-α and IFN- compared to unexposed loops 
(p <0.001).  IFN- was higher in parenterally fed piglets compared to sow-fed pigs (p < 0.01). 
Co-perfusion of fMLP and cysteinyl-glycine resulted in a lower IFN- response in both sow-fed 
and parenterally fed piglets (p < 0.05), but neither group responded significantly to free cys + 
gly.  Interestingly, free cys + gly reduced the TNF-α response in sow-fed pigs (p < 0.001), but 
not in the PN-fed group.  Loops exposed to cysteinyl-glycine and fMLP had lower TNF-α 
concentrations compared to fMLP alone in both diet groups (p < 0.001) and in sow-fed piglets 
the response was significantly more abated than with cys + gly (p < 0.001).  Interleukin-10, an 
anti-inflammatory cytokine, was lower in animals undergoing parenteral nutrition compared to 
sow-fed (p < 0.05), but did not differ between loop treatments.  Morphologically, fMLP exposure 
did not alter villus height or crypt depth in sow-fed animals; in contrast, intestinal segments from 
PN-fed piglets exposed to fMLP had reduced villus height compared to unexposed loops (p < 
0.05).  Inclusion of cysteinyl-glycine was effective at attenuating a bacterial peptide-induced 
inflammatory response in the injured SI; this may be due to efficient dipeptide uptake in a 
situation of impaired free amino acid absorption, and/or competitive inhibition of fMLP uptake.  
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4.2 Introduction 
 
The products of protein digestion that are absorbed by the small intestinal epithelium 
include free amino acids and small peptides of two to three residues in length.  These di/tri-
peptides are removed from the nutrient rich intestinal lumen by a H
+
/peptide symporter, peptide 
transporter 1 or PepT1 (Vig et al., 2006).  This transporter is localized to the apical surface of the 
intestinal villi and has broad substrate specificity.  It is important to note that potential substrates 
for PepT1 include almost all possible dietary di/tripeptides (Vig et al., 2006), some antibiotics 
(Terada et al., 1997, Terada et al., 1998, Zhang et al., 2009) and pro-inflammatory bacterial 
peptides (Shi et al., 2006c, Carlson et al., 2007, Buyse et al., 2001, Dalmasso et al., 2010).   
The primary neutrophil chemotactic substance produced by Escherichia coli is formyl-
methionyl-leucyl-phenylalanine (fMLP) (Marasco et al., 1984).  This tripeptide is the most 
predominant N-formylated peptide present in the colonic lumen of humans (Marasco et al., 
1984).  PepT1-mediated transport of fMLP has been demonstrated in cell culture (Merlin et al., 
1998, Foster and Zheng, 2007) and in vivo in rats (Buyse et al., 2002, Shi et al., 2006a).  Uptake 
of fMLP was inhibited by the presence of known substrates of PepT1 in cell culture studies 
(Merlin et al., 1998, Foster and Zheng, 2007).  Further, the presence of fMLP induced neutrophil 
migration across an epithelial monolayer, an activity which was abolished if fMLP uptake was 
inhibited.  Uptake of fMLP has been investigated in rats using an intestinal perfusion approach 
(Buyse et al., 2002).  Marked inflammatory response occurred in jejunal segments perfused with 
fMLP, an intestinal position known to have high expression of PepT1.  This inflammation was 
accompanied by an increase in DNA binding by NFκβ, a transcription factor involved in the 
regulation of pro-inflammatory cytokines. The transcription factor NFκβ is a key regulator of the 
immune response (Baeuerle and Henkel, 1994). This transcription factor it capable of inducing 
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transcription of TNF-α, a potent pro-inflammatory cytokine involved in inflammatory disease.  
Similarly, NFκβ is capable of promoting the transcription of IFN-γ (Sica et al., 1997), another 
pro-inflammatory cytokine.  Therefore the induction of NFκβ by fMLP may also increase the 
concentration of IFN-γ and TNF-α.  Competitive inhibition of fMLP transport or direct 
regulation of PepT1 expression may have the potential to ameliorate intestinal inflammation in 
pathological situations where there is an abnormally high exposure of bacterial peptides to 
PepT1. 
The necessity for parenteral nutrition (PN) support represents a pathological situation for 
the gut that is characterized by greater intestinal permeability with potential for intestinal atrophy 
(Buchman et al., 1995).  Furthermore, PN modulates the immune response of the intestine 
leading to higher risk of infection (Omata et al., 2013, Heneghan et al., 2013).  This risk is 
potentiated via the suppression of the bactericidal response of the small intestine (Omata et al., 
2013) and a reduction in Paneth cell function leading to an inability to replenish lost enterocytes 
(Heneghan et al., 2013).  A study measuring mRNA of amino acid transporters of parenterally 
and orally fed adult rats noted an increase in PepT1 mRNA in the distal small intestine (Howard 
et al., 2004).  This combination of sustained PepT1 with bacterial overgrowth in the small 
intestine, or bacterial infection due to parenteral nutrition, may facilitate greater uptake of 
bacterial peptides leading to the development of intestinal inflammation.   
We used a piglet model of PN in combination with a ligated loop model of intestinal 
perfusion to investigate changes in cytokine response and intestinal morphology after perfusion 
with fMLP alone or in combination with a competitor for PepT1, the dipeptide cysteinyl-glycine. 
The purpose of this study was to quantify the inflammatory response to fMLP in the distal small 
intestine of piglets with PN-induced intestinal changes, compared to healthy sow-fed littermates.  
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Further, we determined whether the mucosal response to fMLP was altered when presented to 
the small intestine with a dipeptide (cysteinyl-glycine), or the constituent free amino acids (L-
cysteine and glycine).    The selection of cysteinyl-glycine as the dipeptide for this study was 
based on the anti-inflammatory capacity of cysteine (Jones, 2006), as well as previous work 
having demonstrated that cysteinyl-glycine was able to reduce the mucosal concentration of pro-
inflammatory cytokines in a piglet model of short bowel syndrome (Chapter 3) 
4.3 Materials and Methods 
 
4.3.1 Study design 
 
All experimental procedures were approved by the Institutional Animal Care Committee 
in accordance with guidelines of the Canadian Council of Animal Care.  Yucatan miniature 
piglets were randomized to either parenteral nutrition (PN, N = 6) or sow-feeding (N = 6) as 
littermate pairs.  The littermates assigned to PN were removed from the sow at 10 d of age and 
underwent surgical insertion of jugular and femoral catheters, as previously described (Ch 3, pg 
64).  The catheters were implanted for blood sampling and delivery of the parenteral solution. 
PN was initiated immediately following surgery and continued until day four post-operatively as 
short term parenteral feeding (48 hrs) is capable of inducing intestinal atrophy (Niinikoski et al. 
2004).  The sow-fed group remained with the sow during this time.  The complete parenteral diet 
provided 1.1 MJ of metabolizable energy·kg
–1
·d
–1 
with glucose (24.5 g·kg
–1
·d
–1
) and lipid (20% 
Intralipid, Pharmacia) each supplying 50% of non-protein energy and 15 g·kg
–1
·d
–1
 of protein, 
supplied as free amino acids.  The amino acid composition was as follows (per gram of total L-
amino acids): alanine, 107 mg; arginine, 67 mg; aspartate, 61 mg; cysteine, 14 mg; glutamate, 
105 mg; glycine, 27 mg; histidine, 31 mg; isoleucine, 46 mg; leucine, 104 mg; lysine-HCl, 102 
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mg; methionine, 19 mg; phenylalanine, 55 mg; proline, 83 mg; serine, 56 mg; taurine, 5 mg; 
threonine, 41 mg; tryptophan, 21 mg; tyrosine, 8 mg; and valine, 53 mg (Dodge et al., 2012).  
Prior to feeding, vitamins (Multi-12K1 Pediatric, Sabex, St Boucherville, QC) trace minerals at 
200% of NRC recommendations, (NRC, 1998), lipid, and iron dextran (Fe, 3.0 mg/kg; 
Vetoquinol Canada Inc, Saint-Hyacinthe, QC) were added to the diet.   
 
4.3.2 In situ perfusion (gut loop model)  
 
On d 4 of study (d 4 post-op for PN piglets), sow-fed and PN piglets were brought to the 
laboratory to undergo an in situ perfusion study.  The piglets were pre-anesthetized with an IM 
injection of ketamine (20 mg/kg) plus acepromazine (0.5 mg/kg).  Subsequently, the piglets were 
intubated and maintained under general anesthesia using 0.6-1.0% isoflurane (Abbott 
Laboratories Ltd, Montreal, QC) mixed with oxygen at a flow rate of 1.5 L/min.  A laparotomy 
was performed to expose the small intestine. The sites for the five intestinal loops were located 
along the length of the distal small intestine (i.e., ileum).  Closed loops of intestine consisted of 
10 cm sections of intestine with inlet and outlet cannulas (inner diameter, 0.2 cm; outer diameter, 
0.3 cm, Watson Marlow Pumps Group, Wilmington, MA) inserted through a small perforation at 
both ends of the 10 cm.  A suture was placed around the tube and intestine, occluding flow of 
intestinal contents into that section.  The loop was gently flushed of luminal contents using 
warmed (37°C) KRB  (constituents in g/L: D-glucose 1.8, magnesium chloride (anhydrous) 
0.0468, potassium chloride 0.34, sodium chloride 7.0, sodium phosphate dibasic (anhydrous) 0.1 
and sodium phosphate monobasic (anhydrous) 0.18) buffer until the effluent ran clear. Loops 
were separated by 30 cm of intestine with the last loop being placed 50 cm from the ileocecal 
valve.  Piglets were kept warm by a homeothermic blanket and the exposed intestines were kept 
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moistened with warmed saline and covered with gauze and plastic wrap.  Heart rate, body 
temperature and blood oxygenation were monitored throughout the 180 min experiment, after 
which the loops were excised by cautery and flushed with cold 0.9% saline.  A 2-cm segment of 
loop tissue was immersed in neutral buffered 10% formalin (Fisher Scientific, Pittsburgh, PA) 
for histologic analyses.  The remaining segment was placed on ice, cut longitudinally and 
scraped with a microscope slide to remove the mucosa which was then frozen in liquid nitrogen 
and stored at -80°C for further analysis. 
4.3.3 Perfusates 
 
Five different loop treatments (perfusates) were randomly assigned to intestinal position 
with treatments matched for location between littermates.  The treatments contained: 1) 5 mM 
cysteine + glycine; 2) 5 mM cysteinyl-glycine; 3) 10 µM fMLP; 4) 5 mM cysteine +glycine + 10 
µM fMLP; 5) 5 mM cysteinyl-glycine + 10 µM fMLP.  The concentration of dipeptide was 
selected due to the work of Klang et al. (2005) while the concentration of fMLP was selected due 
to previously published work by Buyse et al. (2002). All perfusates were constructed in KRB. 
The fMLP treatment also included 
3
H-fMLP and all loops contained 
14
C-mannitol to assess 
intestinal permeability.  The disappearance of 
3
H-fMLP and 
14
C-mannitol from the perfusates 
was determined by adding 100 µL of perfusate to 4 ml Scintiverse (Fisher Scientific, Pittsburgh, 
PA) for liquid scintillation counting.  The specific radioactivity was calculated as the mean 
dpm/mmol of 
3
H-fMLP or 
14
C-mannitol present in the perfusate. Specific radioactivity was 
calculated at baseline (prior to perfusion) and in each of the perfusate samples taken over the 
course of the 3 h study.  The specific radioactivity was then used to determine the total quantity 
of fMLP or mannitol remaining in the perfusates at the time points studied.  
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4.3.4 TNF-α, IFN- and IL-10 
 
Mucosal TNF-α, IFN- and IL-10 concentrations were determined via porcine ELISA 
kits (Pierce, Rockford, IL).  The kits utilized anti-human antibodies that cross react with porcine 
cytokines.  Tissue supernatants were prepared by homogenizing tissue in PBS containing 
Protease Inhibitor Cocktail III (Calbiochem, Etobicoke, ON) and 1 mM PMSF (Sigma Aldrich, 
Oakville, ON).  Homogenates were then centrifuged at > 10,000 g for 5 minutes at 4 ˚C to allow 
for analysis of tissue supernatants according to the protocol provided by the supplier.  
Absorbance of the enzyme-substrate product was determined by subtracting the calculated value 
at 550 nm from that determined at 450 nm.  Linear regression was used to calculate the final 
concentration of cytokine in the supernatant which was reported as pg per gram of mucosa.  
4.3.5 Myeloperoxidase (MPO) Assay 
 
Intestinal tissue samples (50-100 mg) were homogenized on ice in 0.5% 
hexadecyltrimethylammonium bromide (Sigma Aldrich, Oakville, ON) in 50 mM KPO4.  
Homogenates underwent three rapid freeze/thaw cycles (-80°C/37°C) and were then centrifuged 
at12,800 g for 15 minutes at 4°C.  The supernatant containing MPO was assayed 
spectrophotometrically after the addition of 50 mM KPO4 containing 0.53 mM O-dianisidine 
dihydrochloride and 0.15 mM hydrogen peroxide.  Changes in absorbance were measured at 460 
nm for 2 minutes with readings taken every 15 seconds (BU-530, Beckman Coulter, 
Mississauga, ON).  MPO activity was reported as IU/g wet tissue where one IU was defined as 
the quantity of enzyme able to convert 1 µmol of hydrogen peroxide to water in 1 min at room 
temperature.   
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4.3.6 Histological analysis 
 
4.3.6.1 Preparation of slides 
 
After fixation in 10% buffered formalin (Fisher Scientific, Pittsburgh, PA), samples of 
intestine were dehydrated in ethanol, cleared in xylene, embedded in paraffin wax, and sliced 
into 5-µm sections. 
4.3.6.2 Crypt Depth/Villus Height 
 
Sections were stained with hematoxylin and eosin (Fisher Scientific, Pittsburgh, PA). 
Villus height and crypt depth were measured with a Zeiss Axiostar microscope (Carl Zeiss, 
Toronto, ON).  Images were captured with an Infinity 1 camera and Infinity Analyze software 
(Lumenera Corporation, Nepean, ON). Ten measurements of villus height and crypt depth were 
performed per sample.  All histological measurements were performed in a blinded manner by a 
single investigator (MGN). 
4.3.7 Statistical Analysis 
 
For all analyses a mixed model two-way ANOVA was used, with loop treatment as the 
repeated measure within pigs and diet as the second variable.  Piglets receiving parenteral 
feeding were matched to sow-fed littermates of the same gender.  Differences were determined 
to be significant if p < 0.05 (Graphpad Prism 5.0, La Jolla, CA) 
4.4 Results 
 
Throughout the perfusion studies all piglets remained stable, well-oxygenated and 
maintained a core body temperature between 37-39°C.  
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4.4.1 Mucosal Cytokines 
 
Parenteral nutrition did not affect mucosal IFN-γ concentrations (Fig. 4.1), as the 
concentrations were similar to the sow-fed group when not exposed to fMLP.  Perfusion of 
intestinal loops with fMLP alone significantly increased the concentration of IFN- γ.  Co-
perfusion of fMLP with CG resulted in significantly lower concentrations of IFN- γ in PN fed 
piglets; however this effect was not detected when fMLP was co-perfused with free cysteine and 
glycine.  Similar to the IFN-γ response, there was no effect of parenteral feeding on mucosal 
TNF- concentrations (Fig.4.2).  Perfusion of fMLP resulted in a greater concentration of TNF-
 compared to the control loops, regardless of the presence of either cysteine + glycine or 
cysteinyl-glycine.  Treatment with fMLP and amino acids demonstrated that there was a 
significant effect of the form of amino acids.  Compared to fMLP alone, the dipeptide resulted in 
lower TNF- concentrations stimulated by fMLP in both sow-fed and parenterally-fed piglets.  
Sow-fed piglets had lower TNF- responses to fMLP compared to PN animals when either free 
cysteine and glycine or the dipeptide were added to the perfusate.  The mucosal concentration of 
Il-10 was not affected by any loop treatment; however, piglets receiving parenteral nutrition had 
lower concentrations of the anti-inflammatory cytokine than their sow-fed littermates (Fig. 4.3). 
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Figure 4.1:  Mucosal IFN-γ concentration in sow-fed and PN-fed piglets sampled from ligated 
loops perfused with cysteine + glycine (C+G), cysteinyl-glycine (C-G), formyl-methionyl-
leucyl-phenylalanine (fMLP), a combination of cysteine + glycine + fMLP (C+G+fMLP) or 
cysteinyl-glycine + fMLP (C-G+fMLP).  Lines represent significant differences between diet 
treatments (** p < 0.01).  Differing letters indicate differences amongst loop treatments within 
the diet treatment (p < 0.05).  Data were analyzed via mixed model 2-way ANOVA with 
Bonferroni post-hoc analysis.  N = 6 per group. Values are mean + SD.  
 
 
 
117 
 
 
Sow Fed PN
0
40
80
120
fMLP
C+G+fMLP
C-G+fMLP
C+G
C-G
a a
b
c
d
aa
b b,c
c
**
**
T
N
F
- 
 (
p
g
/g
 t
is
s
u
e
)
 
 
Figure 4.2: Mucosal TNF-α concentration in sow-fed and PN-fed piglets sampled from ligated 
loops perfused with cysteine + glycine (C+G), cysteinyl-glycine (C-G), formyl-methionyl-
leucyl-phenylalanine (fMLP), a combination of cysteine + glycine + fMLP (C+G+fMLP) or 
cysteinyl-glycine + fMLP (C-G+fMLP).  Lines represent significant differences between diet 
treatments (** p < 0.01).  Differing letters indicate differences amongst loop treatments within 
the diet treatment (p < 0.05). Data were analyzed via mixed model 2-way ANOVA with 
Bonferroni post-hoc test.  N = 6 per group. Values are mean + SD.  
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Figure 4.3: Mucosal IL-10 concentration in sow-fed and PN-fed piglets sampled from ligated 
loops perfused with cysteine + glycine (C+G), cysteinyl-glycine (C-G), formyl-methionyl-
leucyl-phenylalanine (fMLP), a combination of cysteine + glycine + fMLP  (C+G+fMLP) or 
cysteinyl-glycine + fMLP (C-G+fMLP).  Lines represent significant differences between diet 
treatment (** p < 0.01).  Data were analyzed via mixed model 2-way ANOVA with Bonferroni 
post-hoc test.  N = 6 per group. Values are mean + SD.  
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4.4.2 Disappearance of 
3
H-fMLP or 
14
C-mannitol 
 
Perfusates sampled throughout the 3-hour procedure were analyzed to determine 
disappearance of 
3
H-fMLP (Fig. 4.4), as a marker for fMLP transport and 
14
C-mannitol (Fig. 
4.5), an indicator of paracellular transport.  Scintillation counting of the perfusate samples 
revealed highly variable results for the transport of 
3
H-fMLP in all loops, both in PN and sow-
fed piglets, with no significant differences found either between dietary regimen or perfusate 
contents.  Analysis of 
14
C-mannitol disappearance found no change in mannitol concentration 
with any perfusate or in either sow-fed or PN fed piglets. 
4.4.3 Myeloperoxidase activity 
 
Myeloperoxidase activity was measured in the intestinal mucosa as an indicator of 
neutrophil migration.  There was no effect of route of feeding on basal myeloperoxidase activity 
(Fig. 4.6).  Perfusion of intestinal segments with fMLP generated greater MPO activity in both 
groups, regardless of dietary regimen. The inclusion of cysteine + glycine with fMLP had no 
impact on MPO activity, but co-perfusion of cysteinyl-glycine with fMLP resulted in lower MPO 
activity that was similar to that of the control samples in both sow-fed and PN piglets.    
4.4.4 Intestinal morphology 
 
There was no effect of route of feeding or loop treatment on crypt depth (Figure 4.7).  In the 
sow-fed animals, villus height was unaffected by exposure to fMLP.  In the PN group, however, 
villi were significantly shorter in the loops perfused with fMLP, and co-perfusion with either 
cysteine and glycine or cysteinyl-glycine were intermediate between the control and fMLP  
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Figure 4.4: Disappearance of fMLP in in sow-fed and PN-fed piglets with intestinal loops 
perfused with either a) formyl-methionyl-leucyl-phenylalanine (fMLP), b) a combination of 
cysteine + glycine + fMLP (C+G+fMLP), or c) cysteinyl-glycine + fMLP (C-G+fMLP).  Data 
were analyzed via mixed model 2-way ANOVA with Bonferroni post-hoc test. N = 6 per group. 
Mean ± SD 
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Figure 4.5:  Disappearance of mannitol in in sow-fed and PN-fed piglets with intestinal loops 
perfused with either a) cysteine + glycine (C+G) b) cysteinyl-glycine (C-G) c)formyl-methionyl-
leucyl-phenylalanine (fMLP) d) a combination of cysteine + glycine + fMLP  (C+G+fMLP) e) 
cysteinyl- glycine + fMLP (C-G+fMLP).  Data were analyzed via mixed model 2-way ANOVA 
with Bonferroni post-hoc. N = 6 per group. Mean ± SD 
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Figure 4.6: Mucosal myeloperoxidase activity in ligated loops in sow-fed and PN-fed piglets 
sampled from ligated loops perfused with cysteine + glycine (C+G), cysteinyl-glycine (C-G), 
formyl-methionyl-leucyl-phenylalanine (fMLP), a combination of cysteine + glycine + fMLP  
(C+G+fMLP) or cysteinyl-glycine + fMLP (C-G+fMLP).  Differing letters represent significant 
differences between loop treatments within a feeding group (p < 0.05).  Data were analyzed via 
mixed model 2-way ANOVA with Bonferroni post-hoc.  N = 6 per group. Values are mean + 
SD.  
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Figure 4.7: Villus height (>0)  and crypt depth (<0) of ligated loops in sow-fed and PN-fed 
piglets sampled from ligated loops perfused with cysteine + glycine (C+G), cysteinyl-glycine (C-
G), formyl-methionyl-leucyl-phenylalanine (fMLP), a combination of cysteine + glycine + fMLP  
(C+G+fMLP) or cysteinyl-glycine + fMLP (C-G+fMLP).  Differing letters represent significant 
differences between loop treatments within parenterally fed animals (p < 0.05).  Lines represent 
significant differences between diet treatment (** p < 0.01).  Data were analyzed via mixed 
model 2-way ANOVA with Bonferroni post-hoc test.  N = 6 per group. Values are mean ± SEM. 
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segments.  Interestingly, villus damage in response to fMLP occurred only in the PN animals 
compared to identical conditions in sow-fed piglets. 
4.5 Discussion 
The objectives of this study were to investigate the mucosal response to fMLP-induced 
inflammation in healthy versus compromised gut and to determine the impact of cysteinyl-
glycine on fMLP-induced inflammation.  These objectives were accomplished through 
quantification of the cytokine response to fMLP, as determined by myeloperoxidase activity and 
intestinal histology.  Not surprisingly, we determined that parenterally-fed animals were more 
susceptible to fMLP-induced inflammation than their sow-fed littermates.  A novel finding is that 
cysteinyl-glycine was more effective at attenuating fMLP-induced inflammation, through the 
reduction of pro-inflammatory cytokines, compared to equimolar amounts of the constituent free 
amino acids. 
 Intestinal mucosa exposed to fMLP had greater concentrations of IFN- and TNF- than 
loops perfused with either free amino acids or cysteinyl-glycine alone.  Previous work on other 
cell types such as neurons (Cianciulli et al., 2009), myeloid cells (Browning et al., 1997) and 
peripheral blood monocytes (Pan et al., 2000) demonstrated that fMLP exposure induces 
expression of NF-κβ.  In turn, NF-κβ can act on the promoter regions for pro-inflammatory 
cytokines such as IFN- and TNF- (Baeuerle and Henkel, 1994, Sica et al., 1997).   In a 
positive feedback loop, TNF- is also capable of inducing NF-κβ activation resulting in the 
propagation of the inflammatory response (Grell et al., 1995).  The function of IFN- is to induce 
the production of chemoattractants for leukocytes; additionally, IFN- is both anti-proliferative 
and apoptotic (Schroder et al., 2004).  Although we did not directly measure NF-κβ, the 
conserved nature of the response to fMLP exposure across numerous cell types combined with 
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the fMLP-induced increase of pro-inflammatory cytokines in the intestine suggests that 
enterocytes may respond to fMLP in a similar fashion.   
Inclusion of a dipeptide as cysteinyl-glycine ameliorated fMLP induced production of 
IFN- and TNF-, potentially through the reduction of PepT1-mediated fMLP uptake via 
competitive inhibition.  It has been well demonstrated that transport of fMLP is inhibited in the 
presence of other PepT1 substrates (Buyse et al., 2002, Shi et al., 2006c, Foster and Zheng, 
2007).  Perfusion of fMLP resulted in a greater concentration of pro-inflammatory cytokines, 
while co-perfusion with cysteinyl-glycine acted as a competitive inhibitor of uptake.  If the 
concentrations of luminal substrates for PepT1 were increased, this could potentially lead to 
further competition for transport and thereby further reduce the inflammatory response induced 
by fMLP. 
Interestingly, co-perfusion of fMLP with free cysteine and glycine significantly reduced 
TNF- only in sow-fed piglets, not their PN-fed littermates.  Cysteine is part of the oxidative 
stress control system, independent of  its role as a component of glutathione (GSH) (Jones, 
2006).  Both cysteine and glycine have been demonstrated to exhibit anti-inflammatory effects in 
arterial endothelial cells through the reduction of NF-κβ activation (Hasegawa et al., 2012).  The 
differing responses by diet treatment may be related to impairment of amino acid uptake 
secondary to PN-induced intestinal atrophy; thus, the tempered response to free cysteine and 
glycine could be due to reduced amino acid availability.   
To determine whether anti-inflammatory cytokines were also affected by route of feeding 
or fMLP exposure, we quantified mucosal concentration of interleukin-10 (IL-10).  Unlike the 
pro-inflammatory cytokines measured, IL-10 concentration was not altered by exposure to 
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fMLP.  Piglets receiving parenteral nutrition, however, had lower mucosal IL-10 compared to 
their sow-fed littermates.  In a mouse model of parenteral nutrition, intestinal epithelial 
lymphocytes produced less IL-10, leading to an overall lower concentration of mucosal IL-10 
compared to mice undergoing enteral feeding (Fukatsu et al., 2001, Sun et al., 2008).  This lack 
of IL-10 synthesis was accompanied by a reduction in tight junction proteins and greater 
epithelial permeability.  Altered intestinal permeability would allow for additional bacterial 
translocation thereby inducing or exacerbating the immune response and intestinal inflammation.   
In order to determine if there was altered ileal paracellular permeability in our piglet 
model, we measured mannitol disappearance from the perfusate during intestinal perfusion.  In a 
Caco-2 cell model, exposure to fMLP reduced intestinal barrier function as indicated by elevated 
mannitol movement (Foster and Zheng, 2007).  The piglet model used in the current study, 
however, studied only the distal intestine rather than whole SI or colon.  Studies in rats have 
shown that the ileum has much lower permeability than either the jejunum or Caco-2 cells, with 
ileal permeability being similar between rats and humans (Artursson et al., 1993, Kim, 1996).   
Parenteral nutrition has also been shown to affect gut barrier function with greater permeability 
to macromolecules in the small intestine (Illig et al., 1992, Iiboshi et al., 1994); however, these 
studies did not directly investigate ileal permeability.  One study in rats did demonstrate greater 
permeability in the ileum after seven days of parenteral nutrition (Mosenthal et al., 2002).  In our 
piglet model, four days of parenteral feeding did not alter permeability in the ileum; however, it 
is unknown if longer duration of PN would result in greater ileal permeability thereby 
potentiating the intestinal inflammatory response to bacteria.  
Quantification of the disappearance of fMLP using a radiolabelled substrate was 
conducted; however, there were no significant differences detected among any of the perfusates 
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or between dietary treatments.  There are two possible explanations for this result. One is that 
there was no difference in the uptake of fMLP from the perfusate.  Alternatively, the method we 
used to quantify fMLP disappearance was not sufficiently sensitive.  Indirect evidence of fMLP 
uptake was provided by the differing concentrations of mucosal cytokines in the presence of the 
bacterial peptide.  Similarly, different mucosal responses depending on whether fMLP was 
perfused alone, with free amino acids or with cysteinyl-glycine suggest that there was potential 
inhibition when a dipeptide was present. This suggests that the detection method is not sensitive 
enough to quantify the movement of 
3
H-fMLP.   If the quantity of radiolabelled fMLP in the 
perfusate were reduced, the ability to detect significance in smaller variations of dpm would be 
increased resulting in a more sensitive assay.  As a surrogate indicator of fMLP transport, and its 
resultant impact on intestinal inflammation, mucosal myeloperoxidase activity was measured. 
Myeloperoxidase activity is useful as a measure of intestinal inflammation.  In this study, 
MPO activity was not affected by intestinal atrophy induced by parenteral nutrition.  However 
cysteinyl-glycine was able to attenuate fMLP induced MPO activity in both sow-fed and PN 
animals.  Previous studies have investigated MPO activity in the small intestine and colon of rats 
(Buyse et al., 2002, Shi et al., 2006c).  These investigations demonstrated that exposure to fMLP 
stimulated MPO activity in the small intestine but only in colonic tissue of rats with PepT1 
expression induced by small bowel resection.  We have demonstrated that supplying a 
competitive inhibitor for fMLP uptake, cysteinyl-glycine, prevents any significant stimulatory 
effect of fMLP on MPO activity.  Although studies have shown competitive inhibition of fMLP 
transport with dipeptides or other substrates of PepT1 (Buyse et al., 2002, Shi et al., 2006c, 
Foster and Zheng, 2007), whether there is an additional benefit due to the presence of a particular 
dipeptide has yet to be determined.  Inclusion of a hydrolysis resistant dipeptide, such as glycyl-
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sarcosine, could potentially further reduce fMLP-induced MPO activity through its stability in 
the lumen of the intestine. 
After four days of parenteral feeding, there was no deleterious effect on the villus 
architecture compared to the sow-fed littermates.  When the challenge of fMLP exposure was 
added, it was apparent that parenteral feeding increased susceptibility to villus damage. 
Destruction of intestinal villi by bacterial peptides would result in reduced nutritional absorptive 
capacity, leading to reduced protein deposition and prolonged recovery for individuals requiring 
parenteral nutrition.  This effect is not limited to the ileum as a study in rats investigated the 
inflammatory effect of fMLP and found similar villus damage in the jejunum after perfusion with 
fMLP (Buyse et al., 2002).  In the current study, the villi damage induced by fMLP was 
ameliorated when either cysteine + glycine or cysteinyl-glycine was included in the perfusate.   
Although the inflammatory effects of bacterial peptides in colonic tissues in cases of 
intestinal injury have been previously investigated (Shi et al., 2006a, Shi et al., 2006c, Merlin et 
al., 2001), this study was the first analysis of fMLP-induced inflammation in a parenterally-fed 
animal model.  We found that parenteral feeding sensitized the ileum to fMLP-induced 
inflammation and that the inclusion of a dipeptide, cysteinyl-glycine, in the lumen of the 
intestine ameliorated this response.  These findings are of particular importance when long-term 
parenteral nutrition is required in neonates, as reduction of pro-inflammatory cytokines could 
reduce risk for intestinal damage.   
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Chapter 5: Summary and Conclusions 
5.1 General Overview 
The series of studies presented in this thesis set out to investigate intestinal dipeptide 
transport via PepT1 in the neonatal Yucatan miniature pig with particular focus on 
developmental changes, intestinal injury and bacterial peptide induced inflammation.  This was 
accomplished through in vivo experimentation using ligated intestinal loops for the study of 
developmental changes and fMLP-induced inflammation.  An 80% jejuno-ileal resection was 
performed to study the ameliorative potential of alanyl-glutamine and cysteinyl-glycine in a 
model of intestinal injury.  The piglet is a model organism for human neonatal development and 
nutrient requirements, with swine also being vital to the agricultural industry in Canada.  As 
such, information on peptide uptake in piglets has important applications in both human health 
and swine husbandry. 
5.2 Investigation of the ontogeny of peptide transport in the piglet 
5.2.1 Overview of results 
The objectives for my first study were to identify the potential for peptide transport in the 
piglet small intestine and determine if there were any differences in peptide transport due to 
developmental changes or dietary alterations. To accomplish this goal, I quantified the 
disappearance of radiolabelled glycyl-sarcosine after perfusion through isolated equidistant 
segments of small intestine from both suckling and post-weaned piglets.  PepT1 mRNA was also 
analysed from the small intestinal loops, as well as samples from the spiral colon, to determine if 
there were any developmental changes in the expression of this peptide transporter.  Through this 
model, I determined that the capacity for dipeptide transport is present in both the proximal and 
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distal small intestine.  By post-weaning, the ileum was the site of highest dipeptide uptake 
compared to jejunal segments.  Analysis of PepT1 mRNA revealed that while PepT1 mRNA was 
present in colonic samples in both suckling and post-weaning animals, after weaning PepT1 
expression was dramatically reduced.   
5.2.2 Implications and modifications 
This study was the first to use the ligated loop model to investigate developmental effects 
on peptide uptake at various locations in the small intestine in piglets.  Characterizing the 
capacity for peptide transport in the neonatal piglet was a vital step in my research programme. 
Knowing the intestinal location where dietary peptides are primarily transported could influence 
surgical decisions such as prioritizing which region of intestine to spare during resection.  
Similarly, armed with the knowledge that peptide transport is possible throughout the intestine, 
dietary regimens could be altered to include di/tripeptides over free amino acid due to favorable 
factors such as increased stability and solubility.  The fact that colonic expression of PepT1 
mRNA was lost after weaning was also an interesting finding.  It is possible that in early life 
there is a greater potential for uptake of harmful bacterial peptides from the lumen of the colon 
than after weaning.    
One of the findings of this work was greater transport in the ileum of post-weaned 
piglets.  Unfortunately it cannot be determined whether this occurs through a developmental 
change, a dietary change or the combination of both.  The study design could have been altered 
to include another group piglets kept on sow’s milk for six weeks.  This would have provided a 
clearer image of the true ontogeny of this transporter; however it would not have been as 
physiologically relevant.  Additionally, direct investigation of the PepT1 protein would have 
been beneficial.  I found highly variable quantities of PepT1 mRNA in the small intestine and 
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relatively small quantities in the colon.  Direct visualization or quantification of PepT1, through 
western blots or immunohistochemistry, would have provided direct information regarding the 
quantity of PepT1 protein present as mRNA content does not always equate with protein 
expression.   
Overall I believe that this initial project was well designed and an excellent launching 
point for the studies which followed.  The use of the ligated loop model allowed for investigation 
of peptide transport at multiple locations in the same animal, dramatically reducing the 
variability.  The choice of substrate, glycyl-sarcosine, controlled for hydrolysis at the brush 
border and inclusion of the radiolabel provided an easy way to track its disappearance.  
As I completed this initial study a piglet model of short-bowel syndrome was being 
characterized.  This model removed the majority of the small intestine but left 100 cm of the 
ileum intact.  As I had previously determined that the ileum was important in the transport of 
dipeptides I was interested in moving my research into this new model.  Was it possible that 
inclusion of dipeptides in an enteral diet would result in increased intestinal adaptation compared 
to equivalent free amino acids in this model of short-bowel syndrome?  
5.3 Investigation of the adaptive benefits of enteral peptides in a surgically shortened gut 
5.3.1 Overview of results 
Continuing my work in peptide transport, my objective was to study the potential 
ameliorative effects of enterally-delivered dipeptides in a surgically shortened intestine using a 
piglet model of short-bowel syndrome.  The piglets underwent surgery at ten days of age as the 
surgical procedure was quite invasive and younger piglets may not have survived the entire 
study.  This piglet model involved the removal of 80% of the small intestine, leaving 100 cm 
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proximal from the ileocecal valve, and performing an anastomosis to the remaining jejunal 
tissue.  After recovery, enteral feeding of dipeptides was initiated and maintained for four days.  
The dipeptides used in this study were alanyl-alanine, as a control for the effect of dipeptides 
alone, alanyl-glutamine (AQ), as a stable form of glutamine, and cysteinyl-glycine (CG), a 
dipeptide providing two residues required for glutathione synthesis as well as amino acids that 
have previously demonstrated anti-inflammatory characteristics.  Using control groups provided 
with equimolar free amino acid diets, and a synergistic dietary regimen of a combination of 
alanyl-glutamine and cysteinyl-glycine (AQ+CG), I was able to determine that there is no 
explicit morphological benefit of enteral dipeptides compared to equimolar free amino acids.  
However, provision of enteral dipeptides did reduce mucosal concentrations of the pro-
inflammatory cytokines TNF-α and IFN-γ.  Inclusion of CG alone did result in greater 
morphological adaptation, as villus height was greater than either AQ or AQ+CG while crypt 
depth was greater than AQ alone.  Other outcomes measured, including cellular proliferation, 
protein synthesis as well as mucosal and plasma amino acid concentrations, did not differ 
amongst any dietary regimen.   
5.3.2 Implications and modifications 
Surgical resection is a common procedure for neonates and the development of a novel 
dietary regimen that increases intestinal adaptation would be extremely beneficial.  While the 
dipeptides I investigated, AQ and CG, did not stimulate any greater adaptive response than free 
amino acids, the impact on cytokines was an unexpected beneficial result generated through 
post-hoc analysis.  These dipeptides could be of use as supplements to individuals suffering from 
inflammatory bowel disorders to reduce in severity of the inflammatory response. 
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 With a study of this complexity there were complications as well as additional outcomes 
which would have clarified some of the results.  Initially I intended to ensure that each block of 
treatments would be tested simultaneously on littermates, thereby increasing the power of my 
analysis.  Due to complications with litter sizes this, unfortunately, was not possible.  For the 
outcomes that were measured, I theorized that one of the reasons why I did not see adaptive 
responses was due to a missed window of adaptation.  Samples were taken after 4 days of enteral 
feeding, so early adaptive responses may have been missed by this study design.  Altering the 
design to include additional cohorts where sampling could be done at earlier time points would 
have provided the necessary data to confirm this theory but would have required significantly 
more animals.  
Perhaps the aspect of this study which would require the most modification would be the 
investigation of the cytokine response.  Although I determined that TNF-α and IFN-γ 
concentrations were lower in piglets receiving AQ and CG I did not determine the mechanism by 
which this occurred.  The hypothesis that this occurs is through modulation of NFκβ is sound 
however without additional measurements this theory remains unproven and it is likely that these 
dipeptides also alter other cellular signals.  There are a number of additional experiments which 
would have provided the necessary details to clarify the mechanism.  A microarray, followed by 
qPCR validation, would have revealed increases or decreases in a variety of cytokine signalling 
pathway intermediates, while a cytokine array would have given a clearer image of the cytokine 
status after enteral feeding.  
 Bacterial overgrowth was also proposed as a potential explanation for the cytokine 
response.  Biopsy of a mesenteric lymph node and culturing the bacteria present would have 
revealed any increase in bacterial translocation.  However production of bacterial peptides could 
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also have induced the inflammatory response.  This ties into the dual nature of PepT1, capable of 
transporting both dietary as well as bacterial peptides.  Is it possible that the inflammation I 
detected, and the subsequent reduction in the presence of enteral dipeptides, was directed 
through transport of bacterial peptides?   
5.4 Investigation of intestinal susceptibility to bacterial inflammation after parenteral feeding 
5.4.1 Overview of results 
 As my second study had created more questions than answers, the objective I had in 
mind for my third study was to investigate the impact of a bacterial peptide, formyl-methionyl-
leucyl-phenylalanine on ileal inflammation in a model of gut atrophy in the presence of 
cysteinyl-glycine.  This would provide a better understanding of the interaction between a 
bacterial peptide and CG, potentially explaining some of the results found in my second study.  
After four days of parenteral nutrition, distal segments of the small intestine were isolated and 
perfused with combinations of fMLP, free cysteine and glycine or the dipeptide cysteinyl-
glycine.  Similar procedures were performed on sow-fed littermates to compare any impact of 
parenteral feeding on intestinal inflammation. Perfusion of the ligated loops with fMLP led to the 
induction of pro-inflammatory cytokines in both sow and PN-fed piglets, with PN feeding 
potentiating the inflammation induced by fMLP as demonstrated by villus damage only in piglets 
undergoing parenteral feeding.  Mucosal concentration of anti-inflammatory IL-10 also was 
lower in PN-fed piglets compared to sow fed littermates.  Co-perfusion of fMLP with CG 
resulted in lower concentrations of these pro-inflammatory cytokines than fMLP alone.   
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5.4.2 Implications and modifications 
The design of this study developed out of the results of my previous work, hence the 
focus on the distal intestine, the location of the remaining intestine after resection.  Similar to the 
first study, using the gut loop model allowed for many different solutions to be investigated in 
one animal, removing the potential for inter-animal variability and giving the analysis additional 
power. Although increases in bacterial population and translocation following parenteral 
nutrition has been well documented, the finding that parenteral nutrition sensitizes the intestine 
to bacterial peptide-based inflammation is novel.  These findings indicate that inflammation due 
to bacterial peptides is of greater concern for individuals undergoing parenteral nutrition and that 
enteral provision of a dipeptide, cysteinyl-glycine, is advantageous for its capability to reduce or 
inhibit the production of pro-inflammatory cytokines.  Similarly, in cases of bacterial overgrowth 
in the small intestine, enteral provision of cysteinyl-glycine would be beneficial to prevent 
unwanted transport of bacterial peptides.  
Moving from a surgically shortened intestine to a gut loop model was necessary for a 
number of reasons.  Most importantly the fragility of the intestine after resection would cause 
complications for insertion and maintenance of a three hour ligated loop perfusion, and the lack 
of a suitable length of intestine in which to place the loops would make this study impossible to 
complete in the previous model.   Unfortunately, the results of this study do not directly answer 
all the questions raised from the short-bowel work.  I was able to demonstrate that fMLP could 
induce inflammation in the distal intestine and inclusion of CG attenuated this inflammation.  
Whether the mechanism by which CG affects fMLP-induced inflammation is through 
competitive inhibition, direct alteration of cellular signalling or a combination of both was not 
determined by this study design.  Similar to the second study, use of modern genomic/proteomic 
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analysis would have provided the necessary information to elucidate the underlying mechanism 
by which CG was reducing the immune response to fMLP.   
Working within the gut loop model, a few minor alterations to the study design would 
have provided additional information, although not all of it tied directly to the primary objective.  
Although four days of parenteral nutrition has been shown to induce intestinal atrophy, I did not 
demonstrate atrophy in my study.  Implantation of additional loops in the jejunum would have 
provided information regarding potential increases in paracellular transport while histological 
sampling of the proximal intestine would have indicated any alteration in intestinal architecture 
confirming intestinal atrophy.  While the initial objective of the study was to determine the 
impact in the distal intestine, investigation of the proximal intestine would have been relatively 
simple. Under pathological conditions the ileum would undergo bacterial overgrowth to a greater 
extent than the jejunum.  If parenteral nutrition induces greater atrophy in the jejunum the impact 
of bacterial peptides in that region may be noteworthy in cases where the intestine had to be 
surgically shortened thereby exposing jejunal tissue to an increased pathogen load.  During the 
loop excision process if measurements of the exact length and width of each loop were taken, the 
total area of absorption could have been calculated leading to a more precise measurement of 
fMLP and mannitol disappearance.   
5.5 Final thoughts 
I believe that future work following from the studies presented here should focus on two 
particular areas.  Having shown that there are developmental differences in intestinal peptide 
transport, the nutritional relevance and metabolic impact of intact dietary di/tripeptides during 
neonatal development should be elucidated.  Certain dipeptides, such as alanyl-glutamine, have 
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been used in therapeutic formulas for a number of years but there has been little work towards 
understanding the potential benefits of replacing free amino acids with di/tripeptides in neonates. 
The contribution of PepT1 to intracellular signalling should also be investigated.  As 
substrates for this transporter can include bacterial compounds, further understanding of the 
downstream signalling mechanisms of these substrates could provide targets for future 
therapeutic interventions.  It has already been suggested that fMLP acts through NFκβ, but there 
is the potential for dietary substrates of PepT1 to influence cellular signalling either due to an 
activity of the intact dipeptide or simply be increasing intracellular concentration of amino acids.  
Ultimately, a more detailed understanding of PepT1 will directly contribute to the development 
of novel dietary therapies and the enhancement of modern nutrition in both health and disease. 
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